227508	Naloxone reverses the antihypertensive effect of clonidine .|In unanesthetized , spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .|The hypotensive effect of 100 mg / kg alpha - methyldopa was also partially reversed by naloxone .|Naloxone alone did not affect either blood pressure or heart rate .|In brain membranes from spontaneously hypertensive rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .|These findings indicate that in spontaneously hypertensive rats the effects of central alpha - adrenoceptor stimulation involve activation of opiate receptors .|As naloxone and clonidine do not appear to interact with the same receptor site , the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha - methyldopa and the possible role of the opiate in the central control of sympathetic tone .	1:CID:2	R2L	NON-CROSS	58-61	51-52	D008750	alpha - methyldopa|alpha - methyldopa	Chemical	58:203	61:206	2:6	D007022	hypotensive	Disease	51	52	2	1:NR:2	L2R	NON-CROSS	0-1	12-13	D009270	Naloxone|naloxone|Naloxone|naloxone|naloxone	Chemical	0:66:68:119:175	1:67:69:120:176	0:2:3:4:6	D006973	hypertensive|hypertensive|hypertensive	Disease	12:85:158	13:86:159	1:4:5	1:NR:2	L2R	NON-CROSS	51-52	66-67	D009270	Naloxone|naloxone|Naloxone|naloxone|naloxone	Chemical	0:66:68:119:175	1:67:69:120:176	0:2:3:4:6	D007022	hypotensive	Disease	51	52	2	1:NR:2	L2R	NON-CROSS	85-86	87-88	D003000	clonidine|clonidine|clonidine|clonidine|clonidine	Chemical	6:25:87:137:177	7:26:88:138:178	0:1:4:4:6	D006973	hypertensive|hypertensive|hypertensive	Disease	12:85:158	13:86:159	1:4:5	1:NR:2	L2R	CROSS	25-26	51-52	D003000	clonidine|clonidine|clonidine|clonidine|clonidine	Chemical	6:25:87:137:177	7:26:88:138:178	0:1:4:4:6	D007022	hypotensive	Disease	51	52	2	1:NR:2	R2L	CROSS	85-86	58-61	D008750	alpha - methyldopa|alpha - methyldopa	Chemical	58:203	61:206	2:6	D006973	hypertensive|hypertensive|hypertensive	Disease	12:85:158	13:86:159	1:4:5	1:NR:2	R2L	CROSS	201-202	158-159	D003000f	clonidine	Chemical	201	202	6	D006973	hypertensive|hypertensive|hypertensive	Disease	12:85:158	13:86:159	1:4:5	1:NR:2	R2L	CROSS	201-202	51-52	D003000f	clonidine	Chemical	201	202	6	D007022	hypotensive	Disease	51	52	2
354896	Lidocaine - induced cardiac asystole .|Intravenous administration of a single 50 - mg bolus of lidocaine in a 67 - year - old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers .|The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias ; and , thus , this probably represented a true idiosyncrasy to lidocaine .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D008012	Lidocaine|lidocaine|lidocaine	Chemical	0:16:69	1:17:70	0:1:2	D006323	cardiac asystole	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	16-17	28-29	D008012	Lidocaine|lidocaine|lidocaine	Chemical	0:16:69	1:17:70	0:1:2	D003866	depression	Disease	28	29	1	1:NR:2	L2R	NON-CROSS	56-57	69-70	D008012	Lidocaine|lidocaine|lidocaine	Chemical	0:16:69	1:17:70	0:1:2	D001919	bradyarrhythmias	Disease	56	57	2
435349	Suxamethonium infusion rate and observed fasciculations .|A dose - response study .|Suxamethonium chloride ( Sch ) was administered i . v .|to 36 adult males at six rates : 0 . 25 mg s - 1 to 20 mg s - 1 .|The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded .|Six additional patients received a 30 - mg i . v .|bolus dose .|Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score .|The times to first fasciculation , twitch suppression and tetanus suppression were inversely related to the infusion rates .|Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion .|Total fasciculation scores in the 30 - mg bolus group and the 5 - mg s - 1 and 20 - mg s - 1 infusion groups were not significantly different .	1:CID:2	L2R	NON-CROSS	0-1	5-6	D013390	Suxamethonium|Suxamethonium chloride|Sch|Sch	Chemical	0:13:16:66	1:15:17:67	0:2:2:4	D005207	fasciculations|Fasciculations|fasciculation|fasciculation|Fasciculations|fasciculation|fasciculation	Disease	5:87:105:112:127:135:147	6:88:106:113:128:136:148	0:7:7:8:9:9:10	1:NR:2	L2R	NON-CROSS	58-59	66-67	D013390	Suxamethonium|Suxamethonium chloride|Sch|Sch	Chemical	0:13:16:66	1:15:17:67	0:2:2:4	D013746	tetanic|twitch|tetanus	Disease	58:114:117	59:115:118	4:8:8
603022	Galanthamine hydrobromide , a longer acting anticholinesterase drug , in the treatment of the central effects of scopolamine ( Hyoscine ) .|Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) overdosage .|It is longer acting than physostigmine and is used in anaesthesia to reverse the non - depolarizing neuromuscular block .|However , studies into the dose necessary to combating scopolamine intoxication are indicated .	1:CID:2	L2R	NON-CROSS	48-49	50-51	D012601	scopolamine|Hyoscine|scopolamine|hyoscine|scopolamine	Chemical	17:19:46:48:81	18:20:47:49:82	0:0:1:1:3	D062787	overdosage	Disease	50	51	1	1:NR:2	L2R	NON-CROSS	22-24	50-51	D005702	Galanthamine hydrobromide|Galanthamine hydrobromide	Chemical	0:22	2:24	0:1	D062787	overdosage	Disease	50	51	1	1:NR:2	R2L	CROSS	57-58	50-51	D010830	physostigmine	Chemical	57	58	2	D062787	overdosage	Disease	50	51	1
1378968	Effects of uninephrectomy and high protein feeding on lithium - induced chronic renal failure in rats .|Rats with lithium - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .|Newborn female Wistar rats were fed a lithium - containing diet ( 50 mmol / kg ) for 8 weeks and then randomized to normal diet , HP diet ( 40 vs . 19 % ) , NX or HP + NX for another 8 weeks .|Corresponding non - lithium pretreated groups were generated .|When comparing all lithium treated versus non - lithium - treated groups , lithium caused a reduction in glomerular filtration rate ( GFR ) without significant changes in effective renal plasma flow ( as determined by a marker secreted into the proximal tubules ) or lithium clearance .|Consequently , lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion .|Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis .|HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats .|NX caused an additive deterioration in GFR which , however , was ameliorated by HP .|NX + HP caused a further rise in blood pressure in Li - pretreated rats .|The results indicate that Li - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .|In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow , which may be the functional expression of the formation of nonfiltrating atubular glomeruli .|The fractional reabsorption of tubular fluid by the proximal tubules is reduced , leaving the distal delivery unchanged . ( ABSTRACT TRUNCATED AT 250 WORDS ) .	1:CID:2	L2R	NON-CROSS	8-9	11-14	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D007676	chronic renal failure|chronic renal failure	Disease	11:279	14:282	0:11	1:CID:2	L2R	NON-CROSS	179-180	182-183	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D011507	proteinuria|proteinuria	Disease	182:269	183:270	6:10	1:CID:2	L2R	NON-CROSS	179-180	185-186	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D006973	hypertension|hypertension	Disease	185:273	186:274	6:10	not_include	L2R	NON-CROSS	19-20	22-23	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D007674	nephropathy|nephropathy	Disease	22:255	23:256	1:10	not_include	L2R	NON-CROSS	54-56	64-65	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D051437	renal failure|renal failure	Disease	54:197	56:199	1:7	1:NR:2	L2R	NON-CROSS	179-180	189-190	D008094	lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|lithium|Li|Lithium|lithium|Li|Li	Chemical	8:19:64:107:116:121:126:158:163:176:179:212:243:252	9:20:65:108:117:122:127:159:164:177:180:213:244:253	0:1:2:3:4:4:4:4:5:5:6:7:9:10	D005921	glomerulosclerosis	Disease	189	190	6	1:NR:2	R2L	CROSS	279-282	209-210	D003404	creatinine	Chemical	209	210	7	D007676	chronic renal failure|chronic renal failure	Disease	11:279	14:282	0:11	1:NR:2	R2L	CROSS	255-256	209-210	D003404	creatinine	Chemical	209	210	7	D007674	nephropathy|nephropathy	Disease	22:255	23:256	1:10	1:NR:2	R2L	NON-CROSS	209-210	197-199	D003404	creatinine	Chemical	209	210	7	D051437	renal failure|renal failure	Disease	54:197	56:199	1:7	1:NR:2	R2L	CROSS	209-210	182-183	D003404	creatinine	Chemical	209	210	7	D011507	proteinuria|proteinuria	Disease	182:269	183:270	6:10	1:NR:2	R2L	CROSS	209-210	185-186	D003404	creatinine	Chemical	209	210	7	D006973	hypertension|hypertension	Disease	185:273	186:274	6:10	1:NR:2	R2L	CROSS	209-210	189-190	D003404	creatinine	Chemical	209	210	7	D005921	glomerulosclerosis	Disease	189	190	6
1420741	Treatment of Crohn 's disease with fusidic acid : an antibiotic with immunosuppressive properties similar to cyclosporin .|Fusidic acid is an antibiotic with T - cell specific immunosuppressive effects similar to those of cyclosporin .|Because of the need for the development of new treatments for Crohn 's disease , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active , therapy - resistant patients .|Eight Crohn 's disease patients were included .|Fusidic acid was administered orally in a dose of 500 mg t . d . s .|and the treatment was planned to last 8 weeks .|The disease activity was primarily measured by a modified individual grading score .|Five of 8 patients ( 63 % ) improved during fusidic acid treatment : 3 at two weeks and 2 after four weeks .|There were no serious clinical side effects , but dose reduction was required in two patients because of nausea .|Biochemically , an increase in alkaline phosphatases was noted in 5 of 8 cases ( 63 % ) , and the greatest increases were seen in those who had elevated levels prior to treatment .|All reversed to pre - treatment levels after cessation of treatment .|The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn 's disease patients in whom conventional treatment is ineffective .|Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease , we suggest that the role of this treatment should be further investigated .	1:CID:2	L2R	CROSS	133-135	165-166	D005672	fusidic acid|fusidic acid|Fusidic acid|fusidic acid|fusidic acid|fusidic acid	Chemical	6:63:83:133:222:255	8:65:85:135:224:257	0:2:4:7:11:12	D009325	nausea	Disease	165	166	8	1:NR:2	R2L	NON-CROSS	6-8	2-5	D005672	fusidic acid|fusidic acid|Fusidic acid|fusidic acid|fusidic acid|fusidic acid	Chemical	6:63:83:133:222:255	8:65:85:135:224:257	0:2:4:7:11:12	D003424	Crohn 's disease|Crohn 's disease|Crohn 's disease|Crohn 's disease	Disease	2:47:76:232	5:50:79:235	0:2:3:11	1:NR:2	R2L	NON-CROSS	16-17	2-5	D016572	cyclosporin|cyclosporin	Chemical	16:34	17:35	0:1	D003424	Crohn 's disease|Crohn 's disease|Crohn 's disease|Crohn 's disease	Disease	2:47:76:232	5:50:79:235	0:2:3:11	1:NR:2	L2R	NON-CROSS	255-257	262-265	D005672	fusidic acid|fusidic acid|Fusidic acid|fusidic acid|fusidic acid|fusidic acid	Chemical	6:63:83:133:222:255	8:65:85:135:224:257	0:2:4:7:11:12	D015212	inflammatory bowel disease	Disease	262	265	12	1:NR:2	L2R	CROSS	34-35	165-166	D016572	cyclosporin|cyclosporin	Chemical	16:34	17:35	0:1	D009325	nausea	Disease	165	166	8	1:NR:2	L2R	CROSS	34-35	262-265	D016572	cyclosporin|cyclosporin	Chemical	16:34	17:35	0:1	D015212	inflammatory bowel disease	Disease	262	265	12
1601297	Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers .|The electrocardiograms ( ECG ) of 99 cocaine - abusing patients were compared with the ECGs of 50 schizophrenic controls .|Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and bundle branch block .	1:CID:2	L2R	NON-CROSS	35-36	51-53	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D009203	myocardial infarction	Disease	51	53	2	1:CID:2	L2R	NON-CROSS	35-36	57-60	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D002037	bundle branch block	Disease	57	60	2	1:NR:2	R2L	NON-CROSS	8-9	3-5	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D009202	myocardial injury|myocardial injury	Disease	3:47	5:49	0:2	1:NR:2	L2R	NON-CROSS	29-30	35-36	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D012559	schizophrenic	Disease	29	30	1	1:NR:2	L2R	NON-CROSS	35-36	54-55	D003042	cocaine|cocaine|cocaine	Chemical	8:18:35	9:19:36	0:1:2	D007511	ischemia	Disease	54	55	2
1967484	Sulpiride - induced tardive dystonia .|Sulpiride is a selective D2 - receptor antagonist with antipsychotic and antidepressant properties .|Although initially thought to be free of extrapyramidal side effects , sulpiride - induced tardive dyskinesia and parkinsonism have been reported occasionally .|We studied a 37 - year - old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy .|We could not find any previous reports of sulpiride - induced tardive dystonia .	1:CID:2	L2R	NON-CROSS	3-5	6-7	D013469	Sulpiride|Sulpiride|sulpiride|sulpiride|sulpiride	Chemical	0:6:31:62:73	1:7:32:63:74	0:1:2:3:4	D004421	tardive dystonia|dystonia|tardive dystonia	Disease	3:56:76	5:57:78	0:3:4	1:NR:2	L2R	NON-CROSS	31-32	34-36	D013469	Sulpiride|Sulpiride|sulpiride|sulpiride|sulpiride	Chemical	0:6:31:62:73	1:7:32:63:74	0:1:2:3:4	D004409	tardive dyskinesia	Disease	34	36	2	1:NR:2	L2R	NON-CROSS	31-32	37-38	D013469	Sulpiride|Sulpiride|sulpiride|sulpiride|sulpiride	Chemical	0:6:31:62:73	1:7:32:63:74	0:1:2:3:4	D010302	parkinsonism	Disease	37	38	2	1:NR:2	R2L	CROSS	17-18	3-5	D000928	antidepressant	Chemical	17	18	1	D004421	tardive dystonia|dystonia|tardive dystonia	Disease	3:56:76	5:57:78	0:3:4	1:NR:2	L2R	CROSS	17-18	34-36	D000928	antidepressant	Chemical	17	18	1	D004409	tardive dyskinesia	Disease	34	36	2	1:NR:2	L2R	CROSS	17-18	37-38	D000928	antidepressant	Chemical	17	18	1	D010302	parkinsonism	Disease	37	38	2
2234245	Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine .|During an 18 - month period of study 41 hemodialyzed patients receiving desferrioxamine ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of audiovisual toxicity .|6 patients presented clinical symptoms of visual or auditory toxicity .|Moreover , detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients .|Visual toxicity was of retinal origin and was characterized by a tritan - type dyschromatopsy , sometimes associated with a loss of visual acuity and pigmentary retinal deposits .|Auditory toxicity was characterized by a mid - to high - frequency neurosensorial hearing loss and the lesion was of the cochlear type .|Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of hearing loss in 3 patients and partial recovery in 3 .|This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels .|The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine .|Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible .	1:CID:2	R2L	NON-CROSS	8-9	0-4	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D014786	Ocular and auditory toxicity|audiovisual toxicity|visual or auditory toxicity|Visual toxicity|a loss of visual acuity|audiovisual toxicity	Disease	0:45:54:74:93:189	4:47:58:76:98:191	0:1:2:4:4:8	1:CID:2	L2R	CROSS	99-102	127-128	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D012164	pigmentary retinal deposits	Disease	99	102	4	1:CID:2	L2R	CROSS	115-118	127-128	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D006319	neurosensorial hearing loss	Disease	115	118	5	not_include	R2L	NON-CROSS	8-9	0-4	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D006311	Ocular and auditory toxicity|audiovisual toxicity|visual or auditory toxicity|Auditory toxicity|audiovisual toxicity	Disease	0:45:54:103:189	4:47:58:105:191	0:1:2:5:8	not_include	L2R	NON-CROSS	151-153	172-173	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D034381	hearing loss	Disease	151	153	6	1:NR:2	L2R	NON-CROSS	163-164	172-173	D003676	desferrioxamine|desferrioxamine|Desferrioxamine|desferrioxamine|desferrioxamine	Chemical	8:22:127:172:200	9:23:128:173:201	0:1:6:7:8	D064420	toxicity	Disease	163	164	7
2385256	Myasthenia gravis presenting as weakness after magnesium administration .|We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia .|The serum magnesium concentration was 3 . 0 mEq / L , which is usually well tolerated .|The magnesium was stopped and she recovered over a few days .|While she was weak , 2 - Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise , suggesting postsynaptic neuromuscular blockade .|After her strength returned , repetitive stimulation was normal , but single fiber EMG revealed increased jitter and blocking .|Her acetylcholine receptor antibody level was markedly elevated .|Although paralysis after magnesium administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .|Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission .	1:CID:2	R2L	NON-CROSS	6-7	0-2	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D009157	Myasthenia gravis|myasthenia gravis	Disease	0:130	2:132	0:7	1:NR:2	R2L	CROSS	130-132	110-111	D000109	acetylcholine	Chemical	110	111	6	D009157	Myasthenia gravis|myasthenia gravis	Disease	0:130	2:132	0:7	not_include	L2R	NON-CROSS	18-20	26-27	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D009468	neuromuscular disease|postsynaptic neuromuscular blockade	Disease	18:85	20:88	1:4	1:NR:2	L2R	NON-CROSS	23-24	26-27	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D011782	quadriplegic	Disease	23	24	1	1:NR:2	L2R	NON-CROSS	26-27	29-30	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D011225	preeclampsia	Disease	29	30	1	1:NR:2	L2R	NON-CROSS	119-120	121-122	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D010243	paralysis	Disease	119	120	7	not_include	L2R	NON-CROSS	160-161	168-172	D008274	magnesium|magnesium|magnesium|magnesium|magnesium|magnesium	Chemical	6:26:33:50:121:160	7:27:34:51:122:161	0:1:2:3:7:8	D020511	disorder of neuromuscular transmission	Disease	168	172	8	1:NR:2	R2L	CROSS	110-111	85-88	D000109	acetylcholine	Chemical	110	111	6	D009468	neuromuscular disease|postsynaptic neuromuscular blockade	Disease	18:85	20:88	1:4	1:NR:2	R2L	CROSS	110-111	23-24	D000109	acetylcholine	Chemical	110	111	6	D011782	quadriplegic	Disease	23	24	1	1:NR:2	R2L	CROSS	110-111	29-30	D000109	acetylcholine	Chemical	110	111	6	D011225	preeclampsia	Disease	29	30	1	1:NR:2	L2R	CROSS	110-111	119-120	D000109	acetylcholine	Chemical	110	111	6	D010243	paralysis	Disease	119	120	7	1:NR:2	L2R	CROSS	110-111	168-172	D000109	acetylcholine	Chemical	110	111	6	D020511	disorder of neuromuscular transmission	Disease	168	172	8
2505783	Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide .|An experimental study / short communication .|Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis .|The data demonstrate that CAA after i . v .|administration does not contribute to bladder damage .|When instilled directly into the bladder , CAA exerts urotoxic effects , it is , however , susceptible to detoxification with mesna .	1:CID:2	L2R	NON-CROSS	52-53	57-59	C004656	Chloroacetaldehyde|chloroacetaldehyde|CAA|CAA|CAA|CAA	Chemical	0:27:29:52:64:85	1:28:30:53:65:86	0:2:2:2:3:5	D006470	hemorrhagic cystitis	Disease	57	59	2	1:CID:2	L2R	NON-CROSS	52-53	57-59	C004656	Chloroacetaldehyde|chloroacetaldehyde|CAA|CAA|CAA|CAA	Chemical	0:27:29:52:64:85	1:28:30:53:65:86	0:2:2:2:3:5	D003556	hemorrhagic cystitis	Disease	57	59	2	not_include	L2R	CROSS	75-77	85-86	C004656	Chloroacetaldehyde|chloroacetaldehyde|CAA|CAA|CAA|CAA	Chemical	0:27:29:52:64:85	1:28:30:53:65:86	0:2:2:2:3:5	D001745	bladder damage	Disease	75	77	4	1:NR:2	L2R	CROSS	9-10	57-59	D003520	cyclophosphamide	Chemical	9	10	0	D006470	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	9-10	57-59	D003520	cyclophosphamide	Chemical	9	10	0	D003556	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	9-10	75-77	D003520	cyclophosphamide	Chemical	9	10	0	D001745	bladder damage	Disease	75	77	4	1:NR:2	L2R	CROSS	11-12	57-59	D007069	ifosfamide	Chemical	11	12	0	D006470	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	11-12	57-59	D007069	ifosfamide	Chemical	11	12	0	D003556	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	L2R	CROSS	11-12	75-77	D007069	ifosfamide	Chemical	11	12	0	D001745	bladder damage	Disease	75	77	4	1:NR:2	R2L	CROSS	99-100	57-59	D015080	mesna	Chemical	99	100	5	D006470	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	R2L	CROSS	99-100	57-59	D015080	mesna	Chemical	99	100	5	D003556	hemorrhagic cystitis	Disease	57	59	2	1:NR:2	R2L	CROSS	99-100	75-77	D015080	mesna	Chemical	99	100	5	D001745	bladder damage	Disease	75	77	4
2515254	Source of pain and primitive dysfunction in migraine : an identical site ?|Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .|Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group .|Subsequently 20 migraine patients , who developed an early onset attack with frontotemporal nitroglycerin , received the drug in a second induction test at other body areas .|No early onset migraine was observed .|Thus the migraine - inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .|This is not consistent with a CNS origin of migraine attack .	1:CID:2	R2L	NON-CROSS	49-50	44-45	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	24:49:77:106	25:50:78:107	1:2:3:5	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	7:15:44:66:95:101:134:146	8:16:45:67:96:102:135:147	0:1:2:3:4:5:5:6	1:NR:2	R2L	NON-CROSS	118-119	106-107	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	24:49:77:106	25:50:78:107	1:2:3:5	D010146	pain|pain	Disease	2:118	3:119	0:5
2572625	Clotiazepam - induced acute hepatitis .|We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a thienodiazepine derivative .|Clotiazepam withdrawal was followed by prompt recovery .|The administration of several benzodiazepines , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of hepatitis .|This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .	1:CID:2	L2R	NON-CROSS	85-86	87-88	C084599	Clotiazepam|clotiazepam|Clotiazepam|clotiazepam|clotiazepam|clotiazepam	Chemical	0:30:36:53:73:87	1:31:37:54:74:88	0:1:2:3:4:4	D056486	hepatitis|hepatitis|hepatitis|hepatitis|hepatotoxicity	Disease	4:16:67:77:85	5:17:68:78:86	0:1:3:4:4	1:NR:2	L2R	NON-CROSS	18-21	30-31	C084599	Clotiazepam|clotiazepam|Clotiazepam|clotiazepam|clotiazepam|clotiazepam	Chemical	0:30:36:53:73:87	1:31:37:54:74:88	0:1:2:3:4:4	D047508	extensive hepatocellular necrosis	Disease	18	21	1	1:NR:2	R2L	NON-CROSS	33-34	16-17	C013295	thienodiazepine	Chemical	33	34	1	D056486	hepatitis|hepatitis|hepatitis|hepatitis|hepatotoxicity	Disease	4:16:67:77:85	5:17:68:78:86	0:1:3:4:4	1:NR:2	R2L	NON-CROSS	90-91	85-86	D001569	benzodiazepines|benzodiazepines	Chemical	48:90	49:91	3:4	D056486	hepatitis|hepatitis|hepatitis|hepatitis|hepatotoxicity	Disease	4:16:67:77:85	5:17:68:78:86	0:1:3:4:4	1:NR:2	R2L	NON-CROSS	33-34	18-21	C013295	thienodiazepine	Chemical	33	34	1	D047508	extensive hepatocellular necrosis	Disease	18	21	1	1:NR:2	R2L	CROSS	48-49	18-21	D001569	benzodiazepines|benzodiazepines	Chemical	48:90	49:91	3:4	D047508	extensive hepatocellular necrosis	Disease	18	21	1
2632720	Arterial hypertension as a complication of prolonged ketoconazole treatment .|Two of 14 patients with Cushing 's syndrome treated on a long - term basis with ketoconazole developed sustained hypertension .|In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated hypertension 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .|In patient 1 , plasma levels of deoxycorticosterone and 11 - deoxycortisol were elevated .|In patient 2 , in addition to an increase in both deoxycorticosterone and 11 - deoxycortisol levels , plasma aldosterone values were raised , with a concomitant suppression of renin levels .|Our findings show that long - term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid - related hypertension .	1:CID:2	R2L	NON-CROSS	29-30	26-27	D007654	ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	7:26:45:129	8:27:46:130	0:1:2:5	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	NON-CROSS	39-40	29-30	D006854	cortisol	Chemical	39	40	2	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	CROSS	77-78	54-55	D003900	deoxycorticosterone|deoxycorticosterone	Chemical	77:96	78:97	3:4	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	CROSS	79-82	54-55	D003350	11 - deoxycortisol|11 - deoxycortisol	Chemical	79:98	82:101	3:4	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	R2L	CROSS	139-140	104-105	D000450	aldosterone	Chemical	104	105	4	D006973	hypertension|hypertension|hypertension|hypertension	Disease	1:29:54:139	2:30:55:140	0:1:2:5	1:NR:2	L2R	NON-CROSS	7-8	15-18	D007654	ketoconazole|ketoconazole|ketoconazole|ketoconazole	Chemical	7:26:45:129	8:27:46:130	0:1:2:5	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	39-40	15-18	D006854	cortisol	Chemical	39	40	2	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	77-78	15-18	D003900	deoxycorticosterone|deoxycorticosterone	Chemical	77:96	78:97	3:4	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	79-82	15-18	D003350	11 - deoxycortisol|11 - deoxycortisol	Chemical	79:98	82:101	3:4	D003480	Cushing 's syndrome	Disease	15	18	1	1:NR:2	R2L	CROSS	104-105	15-18	D000450	aldosterone	Chemical	104	105	4	D003480	Cushing 's syndrome	Disease	15	18	1
2670794	Effects of an inhibitor of angiotensin converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to intravascular coagulation in the rat .|Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .|Injection of Captopril ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both pulmonary and renal insufficiency in this rat model .|The lung weights were lower and PaO2 was improved in rats given this enzyme - blocking agent .|The contents of albumin in the lungs were not changed , indicating that Captopril did not influence the extravasation of protein .|Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril .|The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone .|It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin ( secondary to an increase in bradykinin ) .|Captopril may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less kidney damage will be produced .	1:CID:2	R2L	NON-CROSS	37-39	26-28	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	NON-CROSS	5-6	12-16	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	5-6	12-16	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	5-6	18-20	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	CROSS	56-57	75-76	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D014947	trauma	Disease	56	57	1	1:NR:2	L2R	CROSS	58-59	75-76	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D018805	sepsis	Disease	58	59	1	1:NR:2	L2R	CROSS	75-76	133-135	D000809	angiotensin|angiotensin	Chemical	5:75	6:76	0:2	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	L2R	NON-CROSS	9-10	12-16	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	9-10	12-16	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	L2R	NON-CROSS	9-10	18-20	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	CROSS	56-57	64-65	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D014947	trauma	Disease	56	57	1	1:NR:2	L2R	CROSS	58-59	64-65	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D018805	sepsis	Disease	58	59	1	1:NR:2	L2R	NON-CROSS	124-125	133-135	D002216	Captopril|Captopril|Captopril|Captopril|Captopril|Captopril	Chemical	9:64:124:150:180:216	10:65:125:151:181:217	0:2:4:5:7:8	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	NON-CROSS	48-52	40-41	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	142-143	84-88	D014508	urea	Chemical	142	143	5	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	200-202	84-88	D000804	Angiotension II	Chemical	200	202	7	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	206-207	84-88	D011464	prostacyclin	Chemical	206	207	7	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	213-214	84-88	D001920	bradykinin	Chemical	213	214	7	D011665	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	NON-CROSS	48-52	40-41	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	142-143	84-88	D014508	urea	Chemical	142	143	5	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	200-202	84-88	D000804	Angiotension II	Chemical	200	202	7	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	206-207	84-88	D011464	prostacyclin	Chemical	206	207	7	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	213-214	84-88	D001920	bradykinin	Chemical	213	214	7	D051437	pulmonary and renal insufficiency|pulmonary and renal insufficiency|pulmonary and renal insufficiency	Disease	12:48:84	16:52:88	0:1:2	1:NR:2	R2L	CROSS	142-143	26-28	D014508	urea	Chemical	142	143	5	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	R2L	CROSS	200-202	26-28	D000804	Angiotension II	Chemical	200	202	7	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	R2L	CROSS	206-207	26-28	D011464	prostacyclin	Chemical	206	207	7	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	R2L	CROSS	213-214	26-28	D001920	bradykinin	Chemical	213	214	7	D004211	intravascular coagulation|intravascular coagulation	Disease	18:26	20:28	0:1	1:NR:2	L2R	NON-CROSS	40-41	56-57	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D014947	trauma	Disease	56	57	1	1:NR:2	L2R	NON-CROSS	40-41	58-59	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D018805	sepsis	Disease	58	59	1	1:NR:2	L2R	CROSS	133-135	170-171	D014148	tranexamic acid|AMCA|AMCA	Chemical	37:40:170	39:41:171	1:1:6	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	142-143	56-57	D014508	urea	Chemical	142	143	5	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	200-202	56-57	D000804	Angiotension II	Chemical	200	202	7	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	206-207	56-57	D011464	prostacyclin	Chemical	206	207	7	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	213-214	56-57	D001920	bradykinin	Chemical	213	214	7	D014947	trauma	Disease	56	57	1	1:NR:2	R2L	CROSS	142-143	58-59	D014508	urea	Chemical	142	143	5	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	CROSS	200-202	58-59	D000804	Angiotension II	Chemical	200	202	7	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	CROSS	206-207	58-59	D011464	prostacyclin	Chemical	206	207	7	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	CROSS	213-214	58-59	D001920	bradykinin	Chemical	213	214	7	D018805	sepsis	Disease	58	59	1	1:NR:2	R2L	NON-CROSS	142-143	133-135	D014508	urea	Chemical	142	143	5	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	264-266	200-202	D000804	Angiotension II	Chemical	200	202	7	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	264-266	206-207	D011464	prostacyclin	Chemical	206	207	7	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8	1:NR:2	R2L	CROSS	264-266	213-214	D001920	bradykinin	Chemical	213	214	7	D007674	Renal damage|kidney damage	Disease	133:264	135:266	5:8
2696505	A randomized comparison of labetalol and nitroprusside for induced hypotension .|In a randomized study , labetalol - induced hypotension and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .|Each patient was subjected to an identical anesthetic protocol and similar drug - induced reductions in mean arterial blood pressure ( BP ) ( 50 to 55 mmHg ) .|Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound hypertension was observed in three patients after discontinuation of nitroprusside .|Labetalol administration was not associated with any of these findings .|Arterial PO2 decreased in both groups .|It was concluded that labetalol offers advantages over nitroprusside .	1:CID:2	L2R	NON-CROSS	16-17	19-20	D007741	labetalol|labetalol|Labetalol|labetalol	Chemical	4:16:107:129	5:17:108:130	0:1:4:6	D007022	hypotension|hypotension|hypotension|reductions in mean arterial blood pressure	Disease	9:19:24:56	10:20:25:62	0:1:1:2	1:CID:2	L2R	NON-CROSS	19-20	21-22	D009599	nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	6:21:105:133	7:22:106:134	0:1:3:6	D007022	hypotension|hypotension|hypotension|reductions in mean arterial blood pressure	Disease	9:19:24:56	10:20:25:62	0:1:1:2	1:CID:2	L2R	NON-CROSS	87-94	105-106	D009599	nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	6:21:105:133	7:22:106:134	0:1:3:6	D016534	increase in heart rate and cardiac output	Disease	87	94	3	1:NR:2	L2R	CROSS	87-94	107-108	D007741	labetalol|labetalol|Labetalol|labetalol	Chemical	4:16:107:129	5:17:108:130	0:1:4:6	D016534	increase in heart rate and cardiac output	Disease	87	94	3	1:NR:2	L2R	CROSS	96-97	107-108	D007741	labetalol|labetalol|Labetalol|labetalol	Chemical	4:16:107:129	5:17:108:130	0:1:4:6	D006973	hypertension	Disease	96	97	3	1:NR:2	L2R	NON-CROSS	96-97	105-106	D009599	nitroprusside|nitroprusside|nitroprusside|nitroprusside	Chemical	6:21:105:133	7:22:106:134	0:1:3:6	D006973	hypertension	Disease	96	97	3	1:NR:2	R2L	CROSS	119-120	56-62	C093415	PO2	Chemical	119	120	5	D007022	hypotension|hypotension|hypotension|reductions in mean arterial blood pressure	Disease	9:19:24:56	10:20:25:62	0:1:1:2	1:NR:2	R2L	CROSS	119-120	87-94	C093415	PO2	Chemical	119	120	5	D016534	increase in heart rate and cardiac output	Disease	87	94	3	1:NR:2	R2L	CROSS	119-120	96-97	C093415	PO2	Chemical	119	120	5	D006973	hypertension	Disease	96	97	3
2924746	Chronic carbamazepine treatment in the rat : efficacy , toxicity , and effect on plasma and tissue folate concentrations .|Folate depletion has often been a problem in chronic antiepileptic drug ( AED ) therapy .|Carbamazepine ( CBZ ) , a commonly used AED , has been implicated in some clinical studies .|A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat .|In the course of developing this model , a common vehicle , propylene glycol , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited weight gain .|Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .|Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment .|The CBZ levels measured in plasma and brain of these animals , however , were below those normally considered protective .|This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat , and , indeed , the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment .	1:CID:2	R2L	NON-CROSS	112-114	109-110	D005481	hexafluorodiethyl ether|HFDE|HFDE	Chemical	112:115:163	114:116:164	5:5:6	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	NON-CROSS	1-2	9-10	D002220	carbamazepine|Carbamazepine|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ	Chemical	1:36:38:65:129:143:183:206	2:37:39:66:130:144:184:207	0:2:2:3:5:6:7:8	D064420	toxicity	Disease	9	10	0	1:NR:2	L2R	NON-CROSS	129-130	131-132	D002220	carbamazepine|Carbamazepine|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ	Chemical	1:36:38:65:129:143:183:206	2:37:39:66:130:144:184:207	0:2:2:3:5:6:7:8	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	NON-CROSS	174-176	183-184	D002220	carbamazepine|Carbamazepine|CBZ|CBZ|CBZ|CBZ|CBZ|CBZ	Chemical	1:36:38:65:129:143:183:206	2:37:39:66:130:144:184:207	0:2:2:3:5:6:7:8	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6	1:NR:2	R2L	NON-CROSS	17-18	9-10	D005492	folate|Folate|folate|folate|folate	Chemical	17:20:68:213:224	18:21:69:214:225	0:1:3:8:8	D064420	toxicity	Disease	9	10	0	1:NR:2	R2L	CROSS	86-88	9-10	D019946	propylene glycol	Chemical	86	88	4	D064420	toxicity	Disease	9	10	0	1:NR:2	R2L	CROSS	112-114	9-10	D005481	hexafluorodiethyl ether|HFDE|HFDE	Chemical	112:115:163	114:116:164	5:5:6	D064420	toxicity	Disease	9	10	0	1:NR:2	L2R	CROSS	68-69	103-104	D005492	folate|Folate|folate|folate|folate	Chemical	17:20:68:213:224	18:21:69:214:225	0:1:3:8:8	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	CROSS	68-69	106-108	D005492	folate|Folate|folate|folate|folate	Chemical	17:20:68:213:224	18:21:69:214:225	0:1:3:8:8	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6	1:NR:2	L2R	NON-CROSS	86-88	103-104	D019946	propylene glycol	Chemical	86	88	4	D012640	seizures|Seizures|seizures|seizures	Disease	103:109:131:166	104:110:132:167	4:5:5:6	1:NR:2	L2R	NON-CROSS	86-88	106-108	D019946	propylene glycol	Chemical	86	88	4	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6	1:NR:2	R2L	NON-CROSS	112-114	106-108	D005481	hexafluorodiethyl ether|HFDE|HFDE	Chemical	112:115:163	114:116:164	5:5:6	D015430	weight gain|weight gain	Disease	106:174	108:176	4:6
2951327	Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs .|In six conscious , trained dogs , maintained on a normal sodium intake of 2 to 4 mEq / kg / day , sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15 - minute i . v .|infusions of human alpha - atrial natriuretic factor .|Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .|The release rate of epinephrine ( control , 6 . 7 + / - 0 . 6 ng / kg / min ) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 + / - 5 % of control ( p less than 0 . 001 ) during 0 . 1 microgram / kg / min and to 63 + / - 5 % ( 0 . 1 greater than p greater than 0 . 05 ) or 95 + / - 13 % ( not significant ) during 0 . 3 or 1 . 0 microgram / kg / min .|Steady state arterial plasma concentrations of atrial natriuretic factor were 39 + / - 10 pg / ml ( n = 6 ) during infusions of saline and 284 + / - 24 pg / ml ( n = 6 ) and 1520 + / - 300 pg / ml ( n = 9 ) during 0 . 03 and 0 . 1 microgram / kg / min infusions of the factor . ( ABSTRACT TRUNCATED AT 250 WORDS ) .	1:CID:2	R2L	NON-CROSS	190-191	187-188	D006830	hydralazine	Chemical	190	191	3	D007022	hypotension	Disease	187	188	3	1:CID:2	R2L	NON-CROSS	192-193	187-188	D005996	nitroglycerin	Chemical	192	193	3	D007022	hypotension	Disease	187	188	3	1:NR:2	L2R	CROSS	22-23	157-158	D012964	sodium	Chemical	22	23	1	D013610	tachycardia	Disease	157	158	3	1:NR:2	L2R	CROSS	22-23	187-188	D012964	sodium	Chemical	22	23	1	D007022	hypotension	Disease	187	188	3	1:NR:2	L2R	NON-CROSS	157-158	163-164	D009638	norepinephrine|norepinephrine	Chemical	43:163	44:164	1:3	D013610	tachycardia	Disease	157	158	3	1:NR:2	L2R	NON-CROSS	163-164	187-188	D009638	norepinephrine|norepinephrine	Chemical	43:163	44:164	1:3	D007022	hypotension	Disease	187	188	3	1:NR:2	L2R	CROSS	157-158	198-199	D004837	epinephrine|epinephrine	Chemical	45:198	46:199	1:4	D013610	tachycardia	Disease	157	158	3	1:NR:2	L2R	CROSS	187-188	198-199	D004837	epinephrine|epinephrine	Chemical	45:198	46:199	1:4	D007022	hypotension	Disease	187	188	3	1:NR:2	R2L	NON-CROSS	190-191	157-158	D006830	hydralazine	Chemical	190	191	3	D013610	tachycardia	Disease	157	158	3	1:NR:2	R2L	NON-CROSS	192-193	157-158	D005996	nitroglycerin	Chemical	192	193	3	D013610	tachycardia	Disease	157	158	3
3192036	Death from chemotherapy in gestational trophoblastic disease .|Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high - risk stage of choriocarcinoma .|Based on this principle a 27 - year old woman , classified as being in the high - risk group ( Goldstein and Berkowitz score : 11 ) , was treated with multiple cytotoxic drugs .|The multiple drug schema consisted of : Etoposide 16 . 213 , Methotrexate , Cyclophosphamide , Actomycin - D , and Cisplatin .|On the first day of the schedule , moderate high doses of Methotrexate , Etoposide and Cyclophosphamide were administered .|Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs , probably originating from the uterus .|Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins , which resulted in an open exchange of tumor plugs to the vascular spaces ; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli .|In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations , such as spontaneous necrosis , must be considered less likely .|Patients with large pelvic tumor loads are , according to existing classifications , at high risk to die and to develop drug resistance .|Notwithstanding these facts our findings suggest that these patients might benefit from relatively mild initial treatment , especially true for patients not previously exposed to this drug .|Close observation of the response status both clinically and with beta - hCG values may indicate whether and when more agressive combination chemotherapy should be started . ( ABSTRACT TRUNCATED AT 250 WORDS ) .	1:CID:2	L2R	CROSS	101-102	123-125	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D011655	pulmonary obstruction	Disease	123	125	5	1:CID:2	L2R	CROSS	99-100	123-125	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D011655	pulmonary obstruction	Disease	123	125	5	1:CID:2	L2R	CROSS	103-104	123-125	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D011655	pulmonary obstruction	Disease	123	125	5	1:NR:2	R2L	CROSS	71-72	0-1	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	76-77	0-1	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	78-79	0-1	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	80-83	0-1	D003609	Actomycin - D	Chemical	80	83	3	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	85-86	0-1	D002945	Cisplatin	Chemical	85	86	3	D003643	Death	Disease	0	1	0	1:NR:2	R2L	CROSS	71-72	4-7	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	76-77	4-7	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	78-79	4-7	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	80-83	4-7	D003609	Actomycin - D	Chemical	80	83	3	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	85-86	4-7	D002945	Cisplatin	Chemical	85	86	3	D031901	gestational trophoblastic disease	Disease	4	7	0	1:NR:2	R2L	CROSS	71-72	26-27	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	76-77	26-27	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	78-79	26-27	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	80-83	26-27	D003609	Actomycin - D	Chemical	80	83	3	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	R2L	CROSS	85-86	26-27	D002945	Cisplatin	Chemical	85	86	3	D002822	choriocarcinoma	Disease	26	27	1	1:NR:2	L2R	CROSS	101-102	146-147	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	101-102	147-148	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	not_include	L2R	CROSS	101-102	211-212	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	101-102	229-231	D005047	Etoposide|Etoposide	Chemical	71:101	72:102	3:4	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	99-100	146-147	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	99-100	147-148	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	not_include	L2R	CROSS	99-100	211-212	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	99-100	229-231	D008727	Methotrexate|Methotrexate	Chemical	76:99	77:100	3:4	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	103-104	146-147	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	103-104	147-148	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	not_include	L2R	CROSS	103-104	211-212	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	103-104	229-231	D003520	Cyclophosphamide|Cyclophosphamide	Chemical	78:103	79:104	3:4	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	80-83	123-125	D003609	Actomycin - D	Chemical	80	83	3	D011655	pulmonary obstruction	Disease	123	125	5	1:NR:2	L2R	CROSS	80-83	146-147	D003609	Actomycin - D	Chemical	80	83	3	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	80-83	147-148	D003609	Actomycin - D	Chemical	80	83	3	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	1:NR:2	L2R	CROSS	80-83	211-212	D003609	Actomycin - D	Chemical	80	83	3	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	80-83	229-231	D003609	Actomycin - D	Chemical	80	83	3	D010386	pelvic tumor	Disease	229	231	8	1:NR:2	L2R	CROSS	85-86	123-125	D002945	Cisplatin	Chemical	85	86	3	D011655	pulmonary obstruction	Disease	123	125	5	1:NR:2	L2R	CROSS	85-86	146-147	D002945	Cisplatin	Chemical	85	86	3	D009369	tumor|tumor|tumor|tumor	Disease	146:167:176:190	147:168:177:191	6:6:6:6	1:NR:2	L2R	CROSS	85-86	147-148	D002945	Cisplatin	Chemical	85	86	3	D009336	necrosis|necrosis	Disease	147:218	148:219	6:7	1:NR:2	L2R	CROSS	85-86	211-212	D002945	Cisplatin	Chemical	85	86	3	D004617	embolism	Disease	211	212	7	1:NR:2	L2R	CROSS	85-86	229-231	D002945	Cisplatin	Chemical	85	86	3	D010386	pelvic tumor	Disease	229	231	8
3409645	Sexual dysfunction among patients with arthritis .|The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis , osteoarthritis and spondyloarthropathy , 130 of whom were pair - matched to controls .|Assessments of marital happiness and depressed mood were also made using the CES - D and the Azrin Marital Happiness Scale ( AMHS ) .|Sexual dysfunctions were found to be common among patients and controls , the majority in both groups reporting one or more dysfunctions .|Impotence was more common among male patients than controls and was found to be associated with co - morbidity and the taking of methotrexate .|Depressed mood was more common among patients and was associated with certain sexual difficulties , but not with impotence .|Marital unhappiness , as indicated by AMHS scores , was not associated with arthritis but was associated with sexual dysfunction , sexual dissatisfaction and being female .	1:CID:2	R2L	NON-CROSS	128-129	108-109	D008727	methotrexate	Chemical	108	109	4	D007172	Impotence|impotence	Disease	85:128	86:129	4:5	not_include	R2L	CROSS	148-150	108-109	D008727	methotrexate	Chemical	108	109	4	D012735	Sexual dysfunction|sexual dysfunction|Sexual dysfunctions|sexual dysfunction	Disease	0:12:62:148	2:14:64:150	0:1:3:6	1:NR:2	R2L	CROSS	143-144	108-109	D008727	methotrexate	Chemical	108	109	4	D001168	arthritis|arthritis|arthritis	Disease	5:10:143	6:11:144	0:1:6	1:NR:2	R2L	CROSS	108-109	20-22	D008727	methotrexate	Chemical	108	109	4	D001172	rheumatoid arthritis	Disease	20	22	1	1:NR:2	R2L	CROSS	108-109	23-24	D008727	methotrexate	Chemical	108	109	4	D010003	osteoarthritis	Disease	23	24	1	1:NR:2	R2L	CROSS	108-109	25-26	D008727	methotrexate	Chemical	108	109	4	D025242	spondyloarthropathy	Disease	25	26	1	1:NR:2	R2L	CROSS	110-112	108-109	D008727	methotrexate	Chemical	108	109	4	D003866	depressed mood|Depressed mood	Disease	42:110	44:112	2:5
3412544	Does paracetamol cause urothelial cancer or renal papillary necrosis ?|The risk of developing renal papillary necrosis or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .|The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of phenacetin , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .|By contrast , we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter .	1:CID:2	R2L	NON-CROSS	64-65	52-55	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D007681	renal papillary necrosis|renal papillary necrosis|renal papillary necrosis|renal papillary necrosis	Disease	6:14:52:100	9:17:55:103	0:1:2:3	1:CID:2	R2L	NON-CROSS	32-33	18-27	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D007680	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:CID:2	R2L	NON-CROSS	32-33	18-27	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D001749	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:NR:2	L2R	NON-CROSS	1-2	3-5	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D014523	urothelial cancer	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	97-98	100-103	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D007681	renal papillary necrosis|renal papillary necrosis|renal papillary necrosis|renal papillary necrosis	Disease	6:14:52:100	9:17:55:103	0:1:2:3	1:NR:2	L2R	NON-CROSS	18-27	34-35	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D007680	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:NR:2	L2R	NON-CROSS	82-84	97-98	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D014516	cancer of the renal pelvis , ureter or bladder|ureteric cancer|cancer of the ureter	Disease	18:82:117	27:84:121	1:2:3	1:NR:2	L2R	NON-CROSS	18-27	34-35	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D001749	cancer of the renal pelvis , ureter or bladder|cancer of the renal pelvis and bladder	Disease	18:72	27:79	1:2	1:NR:2	L2R	NON-CROSS	97-98	107-108	D000082	paracetamol|paracetamol|paracetamol	Chemical	1:34:97	2:35:98	0:1:3	D009369	cancers	Disease	107	108	3	1:NR:2	R2L	CROSS	32-33	3-5	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D014523	urothelial cancer	Disease	3	5	0	1:NR:2	R2L	NON-CROSS	32-33	18-27	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D014516	cancer of the renal pelvis , ureter or bladder|ureteric cancer|cancer of the ureter	Disease	18:82:117	27:84:121	1:2:3	not_include	L2R	CROSS	64-65	107-108	D010615	phenacetin|phenacetin	Chemical	32:64	33:65	1:2	D009369	cancers	Disease	107	108	3
3425586	Dapsone - associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait .|A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis .|Her red blood cells ( RBCs ) had increased incubated Heinz body formation , decreased reduced glutathione ( GSH ) , and decreased GSH stability .|The pentose phosphate shunt activity of the dapsone - exposed AE RBCs was increased compared to normal RBCs .|Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation , the GSH content and GSH stability were normal .|The pentose phosphate shunt activity of the non - dapsone - exposed AE RBCs was decreased compared to normal RBCs .|Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals .|Given the influx of Southeast Asians into the United States , oxidant medications should be used with caution , especially if an infection is present , in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E .	1:CID:2	L2R	NON-CROSS	166-167	170-172	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	5:32:170	7:34:172	0:1:6	1:NR:2	L2R	NON-CROSS	27-28	39-40	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D007918	leprosy	Disease	27	28	1	1:NR:2	L2R	NON-CROSS	39-40	51-52	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D006461	hemolysis	Disease	51	52	1	1:NR:2	L2R	CROSS	166-167	202-203	D003622	Dapsone|dapsone|dapsone|dapsone|dapsone|dapsone	Chemical	0:39:86:107:133:166	1:40:87:108:134:167	0:1:3:4:5:6	D007239	infection	Disease	202	203	7	1:NR:2	R2L	CROSS	69-70	32-34	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	5:32:170	7:34:172	0:1:6	1:NR:2	R2L	CROSS	170-172	125-127	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D000743	hemolytic anemia|hemolytic anemia|hemolytic anemia	Disease	5:32:170	7:34:172	0:1:6	1:NR:2	R2L	CROSS	69-70	27-28	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D007918	leprosy	Disease	27	28	1	1:NR:2	R2L	CROSS	80-82	27-28	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D007918	leprosy	Disease	27	28	1	1:NR:2	R2L	CROSS	69-70	51-52	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D006461	hemolysis	Disease	51	52	1	1:NR:2	R2L	CROSS	80-82	51-52	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D006461	hemolysis	Disease	51	52	1	1:NR:2	L2R	CROSS	119-120	202-203	D005978	glutathione|GSH|GSH|GSH|GSH	Chemical	69:71:76:116:119	70:72:77:117:120	2:2:2:4:4	D007239	infection	Disease	202	203	7	1:NR:2	L2R	CROSS	125-127	202-203	D010428	pentose phosphate|pentose phosphate	Chemical	80:125	82:127	3:5	D007239	infection	Disease	202	203	7
3437726	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol , propafenone , diltiazem , and sparteine .|A 47 - year - old patient suffering from coronary artery disease was admitted to the CCU in shock with III .|AV block , severe hypotension , and impairment of ventricular function .|One week prior to admission a therapy with standard doses of metoprolol ( 100 mg t . i . d .|and then 100 mg b . i . d . ) had been initiated .|Two days before admission diltiazem ( 60 mg b . i . d . ) was prescribed in addition .|Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol ( greater than 3000 ng / ml ) and diltiazem ( 526 ng / ml ) .|The patient recovered within 1 week following discontinuation of antianginal therapy .|Three months later the patient was exposed to a single dose of metoprolol , diltiazem , propafenone ( since he had received this drug in the past ) , and sparteine ( as a probe for the debrisoquine / sparteine type polymorphism of oxidative drug metabolism ) .|It was found that he was a poor metabolizer of all four drugs , indicating that their metabolism is under the same genetic control .|Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience adverse drug reactions when treated with standard doses of one of these drugs alone .|Moreover , the coadministration of these frequently used drugs is expected to be especially harmful in this subgroup of patients .	1:CID:2	L2R	CROSS	46-48	69-70	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D054537	AV block	Disease	46	48	2	1:CID:2	L2R	CROSS	50-51	69-70	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D007022	hypotension	Disease	50	51	2	1:CID:2	L2R	CROSS	53-57	69-70	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D018754	impairment of ventricular function	Disease	53	57	2	1:CID:2	L2R	CROSS	19-20	46-48	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D054537	AV block	Disease	46	48	2	1:CID:2	L2R	CROSS	19-20	50-51	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D007022	hypotension	Disease	50	51	2	1:CID:2	L2R	CROSS	19-20	53-57	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	CROSS	15-16	33-36	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	15-16	42-43	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	167-168	260-263	D008790	metoprolol|metoprolol|metoprolol|metoprolol	Chemical	15:69:125:167	16:70:126:168	0:3:6:8	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	L2R	CROSS	17-18	33-36	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	17-18	42-43	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	17-18	46-48	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D054537	AV block	Disease	46	48	2	1:NR:2	L2R	CROSS	17-18	50-51	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D007022	hypotension	Disease	50	51	2	1:NR:2	L2R	CROSS	17-18	53-57	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	CROSS	171-172	260-263	D011405	propafenone|propafenone	Chemical	17:171	18:172	0:8	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	L2R	CROSS	19-20	33-36	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	19-20	42-43	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	169-170	260-263	D004110	diltiazem|diltiazem|diltiazem|diltiazem	Chemical	19:98:135:169	20:99:136:170	0:5:6:8	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	L2R	CROSS	22-23	33-36	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	L2R	CROSS	22-23	42-43	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D012769	shock	Disease	42	43	1	1:NR:2	L2R	CROSS	22-23	46-48	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D054537	AV block	Disease	46	48	2	1:NR:2	L2R	CROSS	22-23	50-51	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D007022	hypotension	Disease	50	51	2	1:NR:2	L2R	CROSS	22-23	53-57	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	NON-CROSS	239-240	260-263	D013034	sparteine|sparteine|sparteine|sparteine	Chemical	22:185:194:239	23:186:195:240	0:8:8:10	D064420	adverse drug reactions	Disease	260	263	10	1:NR:2	R2L	CROSS	192-193	33-36	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D003324	coronary artery disease	Disease	33	36	1	1:NR:2	R2L	CROSS	192-193	42-43	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D012769	shock	Disease	42	43	1	1:NR:2	R2L	CROSS	192-193	46-48	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D054537	AV block	Disease	46	48	2	1:NR:2	R2L	CROSS	192-193	50-51	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D007022	hypotension	Disease	50	51	2	1:NR:2	R2L	CROSS	192-193	53-57	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D018754	impairment of ventricular function	Disease	53	57	2	1:NR:2	L2R	NON-CROSS	241-242	260-263	D003647	debrisoquine|debrisoquine	Chemical	192:241	193:242	8:10	D064420	adverse drug reactions	Disease	260	263	10
3693336	Triazolam - induced brief episodes of secondary mania in a depressed patient .|Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman .|Features of organic mental disorder ( delirium ) were not present .|Manic excitement was coincident with the duration of action of triazolam .|The possible contribution of the triazolo group to changes in affective status is discussed .	1:CID:2	L2R	NON-CROSS	16-17	22-23	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D001714	mania|mania|Manic	Disease	7:22:41	8:23:42	0:1:3	1:NR:2	L2R	NON-CROSS	10-11	16-17	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D003866	depressed|depressed	Disease	10:25	11:26	0:1	1:NR:2	L2R	CROSS	16-17	31-34	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D019965	organic mental disorder	Disease	31	34	2	1:NR:2	L2R	CROSS	35-36	51-52	D014229	Triazolam|triazolam|triazolam|triazolo	Chemical	0:16:51:58	1:17:52:59	0:1:3:4	D003693	delirium	Disease	35	36	2
3780846	On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats .|The development of tolerance to the muscular rigidity produced by morphine was studied in rats .|Saline - pretreated controls given a test dose of morphine ( 20 mg / kg i . p . ) showed a pronounced rigidity recorded as tonic activity in the electromyogram .|Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .|The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped ( S ) licking and / or gnawing in presence of akinetic or hyperkinetic ( K ) behaviour ( AS / KS group ) , suggesting signs of dopaminergic activation .|The rigidity was considerably decreased in both groups after 20 days ' treatment .|In a further series of experiments , haloperidol ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference .|Haloperidol enhanced the rigidity in the A group .|However , the level in the AS / KS group remained considerably lower than in the A group .|The results suggest that rigidity , which is assumed to be due to an action of morphine in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .|Nevertheless , there occurs some real tolerance to this effect .|The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS / KS group might be due to rapid shifts in the predominance of various DA - innervated structures .	1:CID:2	R2L	NON-CROSS	14-15	10-12	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:28:43:72:101:269	15:29:44:73:102:270	0:1:2:3:3:9	D009127	muscular rigidity|muscular rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity	Disease	10:24:57:95:128:166:219:228:257:303	12:26:58:96:129:167:220:229:258:304	0:1:2:3:4:5:6:7:9:11	1:CID:2	R2L	NON-CROSS	228-229	225-226	D006220	haloperidol|Haloperidol	Chemical	186:225	187:226	6:7	D009127	muscular rigidity|muscular rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity|rigidity	Disease	10:24:57:95:128:166:219:228:257:303	12:26:58:96:129:167:220:229:258:304	0:1:2:3:4:5:6:7:9:11	1:CID:2	L2R	NON-CROSS	101-102	113-114	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:28:43:72:101:269	15:29:44:73:102:270	0:1:2:3:3:9	D018476	akinetic|akinetic	Disease	113:145	114:146	3:4	1:CID:2	L2R	CROSS	101-102	147-148	D009020	morphine|morphine|morphine|morphine|morphine|morphine	Chemical	14:28:43:72:101:269	15:29:44:73:102:270	0:1:2:3:3:9	D006948	hyperkinetic	Disease	147	148	4	1:NR:2	R2L	CROSS	186-187	145-146	D006220	haloperidol|Haloperidol	Chemical	186:225	187:226	6:7	D018476	akinetic|akinetic	Disease	113:145	114:146	3:4	1:NR:2	R2L	CROSS	186-187	147-148	D006220	haloperidol|Haloperidol	Chemical	186:225	187:226	6:7	D006948	hyperkinetic	Disease	147	148	4
3800626	Compression neuropathy of the radial nerve due to pentazocine - induced fibrous myopathy .|Fibrous myopathy is a common , well - known side effect of repeated pentazocine injection .|However , compression neuropathy due to fibrotic muscle affected by pentazocine - induced myopathy has not previously been reported .|In a 37 - year - old woman with documented pentazocine - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .|Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps .|Decompression and neurolysis were performed with good subsequent recovery of function .	1:CID:2	R2L	NON-CROSS	8-9	0-6	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D009408	Compression neuropathy of the radial nerve|compression neuropathy	Disease	0:32	6:34	0:2	1:CID:2	R2L	NON-CROSS	8-9	0-6	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D020425	Compression neuropathy of the radial nerve	Disease	0	6	0	1:CID:2	L2R	NON-CROSS	8-9	11-13	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D005355	fibrous myopathy|Fibrous myopathy|fibrous myopathy|fibrous myopathy	Disease	11:14:63:107	13:16:65:109	0:1:3:3	1:CID:2	L2R	NON-CROSS	8-9	11-13	D010423	pentazocine|pentazocine|pentazocine|pentazocine	Chemical	8:27:40:60	9:28:41:61	0:1:2:3	D009135	fibrous myopathy|Fibrous myopathy|myopathy|fibrous myopathy|fibrous myopathy	Disease	11:14:43:63:107	13:16:44:65:109	0:1:2:3:3
3827439	Recurrent reversible acute renal failure from amphotericin .|A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions .|The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction .|We propose that amphotericin , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to acute renal failure .	1:CID:2	R2L	NON-CROSS	6-7	2-5	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D058186	acute renal failure|acute renal failure|acute renal failure	Disease	2:17:77	5:20:80	0:1:3	1:NR:2	L2R	NON-CROSS	6-7	12-13	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D005355	cirrhosis	Disease	12	13	1	1:NR:2	L2R	NON-CROSS	6-7	15-16	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D013174	sporotrichosis	Disease	15	16	1	not_include	L2R	CROSS	25-27	36-38	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D051437	renal failure	Disease	36	38	2	not_include	L2R	CROSS	52-54	58-59	D000666	amphotericin|amphotericin B|amphotericin	Chemical	6:25:58	7:27:59	0:1:3	D007674	renal dysfunction	Disease	52	54	2
3997294	Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .|A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .|He developed pneumonitis , pleural and pericardial effusions , and a predominantly proximal motor neuropathy .|Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone .|Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .	1:CID:2	R2L	NON-CROSS	9-10	2-6	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D010996	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:CID:2	R2L	NON-CROSS	9-10	2-6	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D010490	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:CID:2	L2R	NON-CROSS	89-90	90-91	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D011014	pneumonitis|pneumonitis	Disease	48:90	49:91	2:4	1:CID:2	L2R	CROSS	58-61	69-70	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D009468	proximal motor neuropathy	Disease	58	61	2	1:NR:2	R2L	CROSS	73-74	50-54	D011239	prednisolone	Chemical	73	74	3	D010996	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:NR:2	R2L	CROSS	101-102	50-54	D013256	steroid	Chemical	101	102	4	D010996	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:NR:2	R2L	CROSS	73-74	50-54	D011239	prednisolone	Chemical	73	74	3	D010490	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	1:NR:2	R2L	CROSS	101-102	50-54	D013256	steroid	Chemical	101	102	4	D010490	pleural and pericardial effusion|pleural and pericardial effusions	Disease	2:50	6:54	0:2	not_include	R2L	NON-CROSS	9-10	7-8	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D009422	neuropathy	Disease	7	8	0	1:NR:2	R2L	CROSS	73-74	7-8	D011239	prednisolone	Chemical	73	74	3	D009422	neuropathy	Disease	7	8	0	1:NR:2	R2L	CROSS	101-102	7-8	D013256	steroid	Chemical	101	102	4	D009422	neuropathy	Disease	7	8	0	not_include	L2R	NON-CROSS	9-10	15-17	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D002318	sinuatrial disease	Disease	15	17	1	1:NR:2	L2R	NON-CROSS	23-24	43-45	D000638	amiodarone|amiodarone|amiodarone|amiodarone|amiodarone	Chemical	9:23:69:89:95	10:24:70:90:96	0:1:3:4:4	D013617	supraventricular tachyarrhythmias	Disease	43	45	1	1:NR:2	R2L	CROSS	73-74	15-17	D011239	prednisolone	Chemical	73	74	3	D002318	sinuatrial disease	Disease	15	17	1	1:NR:2	R2L	CROSS	101-102	15-17	D013256	steroid	Chemical	101	102	4	D002318	sinuatrial disease	Disease	15	17	1	1:NR:2	R2L	CROSS	73-74	43-45	D011239	prednisolone	Chemical	73	74	3	D013617	supraventricular tachyarrhythmias	Disease	43	45	1	1:NR:2	R2L	CROSS	101-102	43-45	D013256	steroid	Chemical	101	102	4	D013617	supraventricular tachyarrhythmias	Disease	43	45	1	1:NR:2	R2L	CROSS	90-91	73-74	D011239	prednisolone	Chemical	73	74	3	D011014	pneumonitis|pneumonitis	Disease	48:90	49:91	2:4	1:NR:2	R2L	NON-CROSS	101-102	90-91	D013256	steroid	Chemical	101	102	4	D011014	pneumonitis|pneumonitis	Disease	48:90	49:91	2:4	1:NR:2	R2L	CROSS	73-74	58-61	D011239	prednisolone	Chemical	73	74	3	D009468	proximal motor neuropathy	Disease	58	61	2	1:NR:2	R2L	CROSS	101-102	58-61	D013256	steroid	Chemical	101	102	4	D009468	proximal motor neuropathy	Disease	58	61	2
4071154	Indomethacin - induced renal insufficiency : recurrence on rechallenge .|We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after indomethacin therapy .|Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria .|Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished .|Since nonsteroidal anti - inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure , they should be used with caution in such patients .	1:CID:2	L2R	NON-CROSS	21-22	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D006947	hyperkalemia	Disease	21	22	1	1:CID:2	L2R	NON-CROSS	26-27	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D005355	cirrhosis	Disease	26	27	1	1:CID:2	L2R	NON-CROSS	28-29	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D001201	ascites	Disease	28	29	1	1:CID:2	L2R	NON-CROSS	31-33	34-35	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D011660	cor pulmonale	Disease	31	33	1	1:CID:2	L2R	NON-CROSS	55-56	61-62	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D009846	oliguria	Disease	61	62	2	1:CID:2	L2R	CROSS	55-56	103-106	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D058186	acute renal failure	Disease	103	106	4	not_include	L2R	NON-CROSS	0-1	3-5	D007213	Indomethacin|indomethacin|indomethacin	Chemical	0:34:55	1:35:56	0:1:2	D051437	renal insufficiency|renal failure	Disease	3:18	5:20	0:1	1:NR:2	R2L	CROSS	71-72	18-20	D011453	prostaglandins	Chemical	71	72	3	D051437	renal insufficiency|renal failure	Disease	3:18	5:20	0:1	1:NR:2	R2L	CROSS	71-72	21-22	D011453	prostaglandins	Chemical	71	72	3	D006947	hyperkalemia	Disease	21	22	1	1:NR:2	R2L	CROSS	71-72	26-27	D011453	prostaglandins	Chemical	71	72	3	D005355	cirrhosis	Disease	26	27	1	1:NR:2	R2L	CROSS	71-72	28-29	D011453	prostaglandins	Chemical	71	72	3	D001201	ascites	Disease	28	29	1	1:NR:2	R2L	CROSS	71-72	31-33	D011453	prostaglandins	Chemical	71	72	3	D011660	cor pulmonale	Disease	31	33	1	1:NR:2	R2L	CROSS	71-72	61-62	D011453	prostaglandins	Chemical	71	72	3	D009846	oliguria	Disease	61	62	2	1:NR:2	L2R	CROSS	71-72	103-106	D011453	prostaglandins	Chemical	71	72	3	D058186	acute renal failure	Disease	103	106	4
6103707	Comparison of the subjective effects and plasma concentrations following oral and i . m .|administration of flunitrazepam in volunteers .|Flunitrazepam 0 . 5 , 1 . 0 or 2 . 0 mg was given by the oral or i . m .|routes to groups of volunteers and its effects compared .|Plasma concentrations of the drug were estimated by gas - liquid chromatography , in a smaller number of the subjects .|The most striking effect was sedation which increased with the dose , 2 mg producing deep sleep although the subjects could still be aroused .|The effects of i . m .|administration were apparent earlier and sometimes lasted longer than those following oral administration .|Dizziness was less marked than sedation , but increased with the dose .|There was pain on i . m .|injection of flunitrazepam significantly more often than with isotonic saline .|Plasma concentrations varied with dose and route and corresponded qualitatively with the subjective effects .|The drug was still present in measurable quantities after 24 h even with the smallest dose .	1:CID:2	L2R	CROSS	121-122	144-145	D005445	flunitrazepam|Flunitrazepam|flunitrazepam	Chemical	17:21:144	18:22:145	1:2:10	D004244	Dizziness	Disease	121	122	8	1:CID:2	L2R	CROSS	136-137	144-145	D005445	flunitrazepam|Flunitrazepam|flunitrazepam	Chemical	17:21:144	18:22:145	1:2:10	D010146	pain	Disease	136	137	9
6229975	Changes in heart size during long - term timolol treatment after myocardial infarction .|The effect of long - term timolol treatment on heart size after myocardial infarction was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .|The follow - up period was 12 months .|The timolol - treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group .|These differences may be caused by timolol - induced bradycardia and a compensatory increase in end - diastolic volume .|The timolol - related increase in heart size was observed only in patients with normal and borderline heart size .|In patients with cardiomegaly , the increase in heart size was similar in both groups .|After re - infarction , heart size increased in the placebo group and remained unchanged in the timolol group .	1:CID:2	L2R	CROSS	107-108	129-130	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D006332	cardiomegaly	Disease	129	130	6	1:NR:2	L2R	NON-CROSS	8-9	11-13	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D009203	myocardial infarction|myocardial infarction	Disease	11:26	13:28	0:1	1:NR:2	L2R	NON-CROSS	92-93	95-96	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D001919	bradycardia	Disease	95	96	4	1:NR:2	L2R	NON-CROSS	145-146	159-160	D013999	timolol|timolol|timolol|timolol|timolol|timolol|timolol	Chemical	8:20:47:61:92:107:159	9:21:48:62:93:108:160	0:1:1:3:4:5:7	D007238	infarction	Disease	145	146	7
6286738	Vitamin D3 toxicity in dairy cows .|Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .|Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum ( 8 . 8 mg / 100 ml ) than in control cows ( 5 . 5 mg / 100 ml ) .|None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .|Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .|There was widespread metastatic calcification in the cows that died .|Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 can not be used practically to prevent milk fever when injected several weeks prepartum .	1:CID:2	L2R	NON-CROSS	25-27	32-33	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D006934	hypercalcemia	Disease	32	33	1	1:CID:2	L2R	NON-CROSS	34-35	40-42	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D054559	hyperphosphatemia	Disease	34	35	1	1:NR:2	L2R	NON-CROSS	0-2	2-3	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D064420	toxicity|toxicity|toxicity|toxicity	Disease	2:137:157:180	3:138:158:181	0:4:4:6	1:NR:2	L2R	NON-CROSS	197-199	201-203	D002762	Vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3|vitamin D3	Chemical	0:11:25:40:68:103:135:155:182:197:213	2:13:27:42:70:105:137:157:184:199:215	0:1:1:1:2:3:4:4:6:6:6	D010319	milk fever|milk fever|milk fever|milk fever|milk fever	Disease	108:127:201:207:222	110:129:203:209:224	3:3:6:6:6	1:NR:2	R2L	CROSS	57-58	2-3	D002118	Calcium	Chemical	57	58	2	D064420	toxicity|toxicity|toxicity|toxicity	Disease	2:137:157:180	3:138:158:181	0:4:4:6	1:NR:2	R2L	CROSS	57-58	32-33	D002118	Calcium	Chemical	57	58	2	D006934	hypercalcemia	Disease	32	33	1	1:NR:2	R2L	CROSS	57-58	34-35	D002118	Calcium	Chemical	57	58	2	D054559	hyperphosphatemia	Disease	34	35	1	1:NR:2	L2R	CROSS	57-58	108-110	D002118	Calcium	Chemical	57	58	2	D010319	milk fever|milk fever|milk fever|milk fever|milk fever	Disease	108:127:201:207:222	110:129:203:209:224	3:3:6:6:6
6287825	Diseases of peripheral nerves as seen in the Nigerian African .|The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders , as seen in 358 Nigerians are presented .|There is a male preponderance and the peak incidence is in the fourth decade .|Sensori - motor neuropathy was the commonest presentation ( 50 % ) .|Guillain - Barr syndrome was the commonest identifiable cause ( 15 . 6 % ) , accounting for half of the cases with motor neuropathy .|Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .|Diabetes mellitus was the major cause of autonomic neuropathy .|Isoniazid was the most frequent agent in drug - induced neuropathy .|Migraine ( 20 % ) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent ( 26 % ) .|In 26 . 5 % of all the cases , the aetiology of the neuropathy was undetermined .|Heredofamilial and connective tissue disorders were rare .|Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed .	1:CID:2	R2L	NON-CROSS	97-98	90-92	D013831	thiamine	Chemical	97	98	5	D010523	Diseases of peripheral nerves|peripheral nerve disease|Sensori - motor neuropathy|motor neuropathy|Peripheral neuropathy|sensori - motor neuropathy	Disease	0:17:51:87:90:114	4:20:55:89:92:118	0:1:3:4:5:5	1:CID:2	R2L	NON-CROSS	99-100	90-92	D012256	riboflavin	Chemical	99	100	5	D010523	Diseases of peripheral nerves|peripheral nerve disease|Sensori - motor neuropathy|motor neuropathy|Peripheral neuropathy|sensori - motor neuropathy	Disease	0:17:51:87:90:114	4:20:55:89:92:118	0:1:3:4:5:5	1:CID:2	R2L	CROSS	129-130	114-118	D007538	Isoniazid	Chemical	129	130	7	D010523	Diseases of peripheral nerves|peripheral nerve disease|Sensori - motor neuropathy|motor neuropathy|Peripheral neuropathy|sensori - motor neuropathy	Disease	0:17:51:87:90:114	4:20:55:89:92:118	0:1:3:4:5:5	1:NR:2	R2L	CROSS	97-98	64-68	D013831	thiamine	Chemical	97	98	5	D020275	Guillain - Barr syndrome	Disease	64	68	4	1:NR:2	R2L	CROSS	99-100	64-68	D012256	riboflavin	Chemical	99	100	5	D020275	Guillain - Barr syndrome	Disease	64	68	4	1:NR:2	R2L	CROSS	129-130	64-68	D007538	Isoniazid	Chemical	129	130	7	D020275	Guillain - Barr syndrome	Disease	64	68	4	1:NR:2	R2L	NON-CROSS	97-98	94-96	D013831	thiamine	Chemical	97	98	5	D044342	nutritional deficiency	Disease	94	96	5	1:NR:2	R2L	NON-CROSS	99-100	94-96	D012256	riboflavin	Chemical	99	100	5	D044342	nutritional deficiency	Disease	94	96	5	1:NR:2	R2L	CROSS	129-130	94-96	D007538	Isoniazid	Chemical	129	130	7	D044342	nutritional deficiency	Disease	94	96	5	1:NR:2	L2R	CROSS	97-98	119-121	D013831	thiamine	Chemical	97	98	5	D003920	Diabetes mellitus	Disease	119	121	6	not_include	L2R	CROSS	97-98	126-128	D013831	thiamine	Chemical	97	98	5	D009422	autonomic neuropathy|neuropathy|neuropathy|neuropathies	Disease	126:139:191:216	128:140:192:217	6:7:9:11	1:NR:2	L2R	CROSS	97-98	141-142	D013831	thiamine	Chemical	97	98	5	D008881	Migraine	Disease	141	142	8	1:NR:2	L2R	CROSS	97-98	152-154	D013831	thiamine	Chemical	97	98	5	D003389	cranial neuropathy	Disease	152	154	8	1:NR:2	L2R	CROSS	97-98	155-156	D013831	thiamine	Chemical	97	98	5	D009369	malignancies	Disease	155	156	8	1:NR:2	L2R	CROSS	97-98	197-200	D013831	thiamine	Chemical	97	98	5	D003240	connective tissue disorders	Disease	197	200	10	1:NR:2	L2R	CROSS	99-100	119-121	D012256	riboflavin	Chemical	99	100	5	D003920	Diabetes mellitus	Disease	119	121	6	not_include	L2R	CROSS	99-100	126-128	D012256	riboflavin	Chemical	99	100	5	D009422	autonomic neuropathy|neuropathy|neuropathy|neuropathies	Disease	126:139:191:216	128:140:192:217	6:7:9:11	1:NR:2	L2R	CROSS	99-100	141-142	D012256	riboflavin	Chemical	99	100	5	D008881	Migraine	Disease	141	142	8	1:NR:2	L2R	CROSS	99-100	152-154	D012256	riboflavin	Chemical	99	100	5	D003389	cranial neuropathy	Disease	152	154	8	1:NR:2	L2R	CROSS	99-100	155-156	D012256	riboflavin	Chemical	99	100	5	D009369	malignancies	Disease	155	156	8	1:NR:2	L2R	CROSS	99-100	197-200	D012256	riboflavin	Chemical	99	100	5	D003240	connective tissue disorders	Disease	197	200	10	1:NR:2	R2L	CROSS	129-130	119-121	D007538	Isoniazid	Chemical	129	130	7	D003920	Diabetes mellitus	Disease	119	121	6	not_include	R2L	NON-CROSS	129-130	126-128	D007538	Isoniazid	Chemical	129	130	7	D009422	autonomic neuropathy|neuropathy|neuropathy|neuropathies	Disease	126:139:191:216	128:140:192:217	6:7:9:11	1:NR:2	L2R	CROSS	129-130	141-142	D007538	Isoniazid	Chemical	129	130	7	D008881	Migraine	Disease	141	142	8	1:NR:2	L2R	CROSS	129-130	152-154	D007538	Isoniazid	Chemical	129	130	7	D003389	cranial neuropathy	Disease	152	154	8	1:NR:2	L2R	CROSS	129-130	155-156	D007538	Isoniazid	Chemical	129	130	7	D009369	malignancies	Disease	155	156	8	1:NR:2	L2R	CROSS	129-130	197-200	D007538	Isoniazid	Chemical	129	130	7	D003240	connective tissue disorders	Disease	197	200	10
6386793	A double - blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder .|In a 6 - week double - blind parallel treatment study , dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients .|Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness , and both were significantly superior to placebo .|The overall incidence of side effects and the frequency and severity of blurred vision , dry mouth , and drowsiness were significantly less with dothiepin than with amitriptyline .|Dothiepin also produced fewer CNS and cardiovascular effects .|There were no clinically important changes in laboratory parameters .|Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients .	1:CID:2	L2R	NON-CROSS	82-84	97-98	D000639	amitriptyline|amitriptyline|amitriptyline|amitriptyline	Chemical	35:50:97:134	36:51:98:135	1:2:3:6	D014786	blurred vision	Disease	82	84	3	1:CID:2	L2R	NON-CROSS	85-87	97-98	D000639	amitriptyline|amitriptyline|amitriptyline|amitriptyline	Chemical	35:50:97:134	36:51:98:135	1:2:3:6	D014987	dry mouth	Disease	85	87	3	1:NR:2	L2R	NON-CROSS	45-46	48-49	D004308	dothiepin hydrochloride|dothiepin|Dothiepin|dothiepin|Dothiepin|Dothiepin	Chemical	11:33:48:94:99:118	13:34:49:95:100:119	0:1:2:3:4:6	D003866	depressive disorder|depressed|depressive illness|depressed	Disease	18:45:59:139	20:46:61:140	0:1:2:6	1:NR:2	L2R	NON-CROSS	82-84	94-95	D004308	dothiepin hydrochloride|dothiepin|Dothiepin|dothiepin|Dothiepin|Dothiepin	Chemical	11:33:48:94:99:118	13:34:49:95:100:119	0:1:2:3:4:6	D014786	blurred vision	Disease	82	84	3	1:NR:2	L2R	NON-CROSS	85-87	94-95	D004308	dothiepin hydrochloride|dothiepin|Dothiepin|dothiepin|Dothiepin|Dothiepin	Chemical	11:33:48:94:99:118	13:34:49:95:100:119	0:1:2:3:4:6	D014987	dry mouth	Disease	85	87	3	1:NR:2	R2L	NON-CROSS	50-51	45-46	D000639	amitriptyline|amitriptyline|amitriptyline|amitriptyline	Chemical	35:50:97:134	36:51:98:135	1:2:3:6	D003866	depressive disorder|depressed|depressive illness|depressed	Disease	18:45:59:139	20:46:61:140	0:1:2:6	1:NR:2	R2L	NON-CROSS	139-140	126-127	D000928	antidepressant	Chemical	126	127	6	D003866	depressive disorder|depressed|depressive illness|depressed	Disease	18:45:59:139	20:46:61:140	0:1:2:6	1:NR:2	R2L	CROSS	126-127	82-84	D000928	antidepressant	Chemical	126	127	6	D014786	blurred vision	Disease	82	84	3	1:NR:2	R2L	CROSS	126-127	85-87	D000928	antidepressant	Chemical	126	127	6	D014987	dry mouth	Disease	85	87	3
6387529	Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia .|The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double - blind , randomized and crossover design .|Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol .|Delayed free recall was also impaired but the two drugs did not differ .|Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol .|After 2 weeks of treatment , patients tested 5 - 8 h after the last dose of medication did not show any decrement of performance .|These results are similar to those previously found in healthy subjects .|Accumulation of drugs was not reflected in prolonged behavioral impairment .	1:CID:2	L2R	NON-CROSS	96-97	100-106	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D008569	impaired immediate free recall|Delayed free recall was also impaired	Disease	86:100	90:106	2:3	1:CID:2	L2R	NON-CROSS	98-99	100-106	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D008569	impaired immediate free recall|Delayed free recall was also impaired	Disease	86:100	90:106	2:3	1:NR:2	L2R	NON-CROSS	3-4	9-11	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D016584	panic disorder|panic disorders	Disease	9:67	11:69	0:1	1:NR:2	L2R	NON-CROSS	12-13	20-21	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D000379	agoraphobia|agoraphobia	Disease	12:70	13:71	0:1	1:NR:2	L2R	CROSS	127-128	177-179	D003975	diazepam|diazepam|diazepam|diazepam|diazepam	Chemical	3:20:96:120:127	4:21:97:121:128	0:1:2:4:4	D001523	behavioral impairment	Disease	177	179	7	1:NR:2	L2R	NON-CROSS	5-6	9-11	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D016584	panic disorder|panic disorders	Disease	9:67	11:69	0:1	1:NR:2	L2R	NON-CROSS	5-6	12-13	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D000379	agoraphobia|agoraphobia	Disease	12:70	13:71	0:1	1:NR:2	L2R	CROSS	129-130	177-179	D011433	propranolol|propranolol|propranolol|propranolol|propranolol	Chemical	5:41:98:118:129	6:42:99:119:130	0:1:2:4:4	D001523	behavioral impairment	Disease	177	179	7
6692345	Effect of aspirin on N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide - induced epithelial proliferation in the urinary bladder and forestomach of the rat .|The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of forestomach tumors .|An autoradiographic study was performed on male F - 344 rats fed diet containing FANFT at a level of 0 . 2 % and / or aspirin at a level of 0 . 5 % to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder .|FANFT - induced cell proliferation in the bladder was significantly suppressed by aspirin co - administration after 4 weeks but not after 12 weeks .|In the forestomach , and also in the liver , aspirin did not affect the FANFT - induced increase in labeling index .|The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach , and that aspirin 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .|Also , there appears to be an adaptation by the rats to the chronic ingestion of aspirin .	1:CID:2	L2R	NON-CROSS	78-79	81-83	D005200	N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT	Chemical	4:46:68:78:105:139:146:186:210:224	25:67:69:79:106:140:147:187:211:225	0:1:1:1:2:2:3:4:5:5	D001749	bladder carcinomas	Disease	81	83	1	1:CID:2	L2R	NON-CROSS	78-79	88-90	D005200	N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT	Chemical	4:46:68:78:105:139:146:186:210:224	25:67:69:79:106:140:147:187:211:225	0:1:1:1:2:2:3:4:5:5	D013274	forestomach tumors	Disease	88	90	1	1:NR:2	L2R	NON-CROSS	81-83	117-118	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	2:44:117:131:158:181:220:257	3:45:118:132:159:182:221:258	0:1:2:2:3:4:5:6	D001749	bladder carcinomas	Disease	81	83	1	1:NR:2	L2R	NON-CROSS	88-90	117-118	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	2:44:117:131:158:181:220:257	3:45:118:132:159:182:221:258	0:1:2:2:3:4:5:6	D013274	forestomach tumors	Disease	88	90	1	1:NR:2	L2R	NON-CROSS	211-212	220-221	D001241	aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin|aspirin	Chemical	2:44:117:131:158:181:220:257	3:45:118:132:159:182:221:258	0:1:2:2:3:4:5:6	D063646	carcinogenesis	Disease	211	212	5	1:NR:2	L2R	NON-CROSS	210-211	211-212	D005200	N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT|FANFT	Chemical	4:46:68:78:105:139:146:186:210:224	25:67:69:79:106:140:147:187:211:225	0:1:1:1:2:2:3:4:5:5	D063646	carcinogenesis	Disease	211	212	5
6773726	Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy ?|The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .|The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .|It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients , particularly those with autonomic neuropathy .	1:CID:2	R2L	NON-CROSS	5-6	3-4	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D007022	hypotension	Disease	3	4	0	1:NR:2	L2R	NON-CROSS	5-6	7-10	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D003929	diabetic autonomic neuropathy	Disease	7	10	0	1:NR:2	L2R	NON-CROSS	63-64	70-71	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D003920	diabetic|diabetic|diabetic|diabetic|diabetic	Disease	30:38:70:94:114	31:39:71:95:115	1:1:2:2:3	1:NR:2	L2R	NON-CROSS	63-64	73-75	D005996	nitroglycerin|nitroglycerin|nitroglycerin	Chemical	5:14:63	6:15:64	0:1:2	D009422	autonomic neuropathy|autonomic neuropathy|autonomic neuropathy|autonomic neuropathy|autonomic neuropathy	Disease	33:41:73:97:120	35:43:75:99:122	1:1:2:2:3
6888657	Characterization of estrogen - induced adenohypophyseal tumors in the Fischer 344 rat .|Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .|Over a range of 1 - 150 days of DES treatment , pairs of control and DES - treated rats were sacrificed , and their pituitaries dissociated enzymatically into single - cell preparations .|The cell populations were examined regarding total cell recovery correlated with gland weight , intracellular prolactin ( PRL ) content and subsequent release in primary culture , immunocytochemical PRL staining , density and / or size alterations via separation on Ficoll - Hypaque and by unit gravity sedimentation , and cell cycle analysis , after acriflavine DNA staining , by laser flow cytometry .|Total cell yields from DES - treated pituitaries increased from 1 . 3 times control yields at 8 days of treatment to 58 . 9 times control values by day 150 .|Intracellular PRL content ranged from 1 . 9 to 9 . 4 times control levels , and PRL release in vitro was significantly and consistently higher than controls , after at least 8 days of DES exposure .|Beyond 8 days of DES exposure , the immunochemically PRL - positive proportion of cells increased to over 50 % of the total population .|Increased density and / or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols .|All these effects of DES were more pronounced among previously ovariectomized animals .|The data extend the findings of other investigators , further establishing the DES - induced tumor as a model for study of PRL cellular control mechanisms .	1:CID:2	R2L	NON-CROSS	25-26	13-15	D004054	diethylstilbestrol|DES|DES|DES|DES|DES|DES|DES|DES	Chemical	25:27:49:56:142:205:212:263:284	26:28:50:57:143:206:213:264:285	1:1:2:2:4:5:6:8:9	D010911	adenohypophyseal tumors|Pituitary tumors	Disease	5:13	7:15	0:1	1:NR:2	L2R	NON-CROSS	2-3	5-7	D004967	estrogen	Chemical	2	3	0	D010911	adenohypophyseal tumors|Pituitary tumors	Disease	5:13	7:15	0:1	1:NR:2	L2R	CROSS	2-3	287-288	D004967	estrogen	Chemical	2	3	0	D009369	tumor	Disease	287	288	9	1:NR:2	R2L	CROSS	129-130	13-15	D000167	acriflavine	Chemical	129	130	3	D010911	adenohypophyseal tumors|Pituitary tumors	Disease	5:13	7:15	0:1	not_include	L2R	NON-CROSS	284-285	287-288	D004054	diethylstilbestrol|DES|DES|DES|DES|DES|DES|DES|DES	Chemical	25:27:49:56:142:205:212:263:284	26:28:50:57:143:206:213:264:285	1:1:2:2:4:5:6:8:9	D009369	tumor	Disease	287	288	9	1:NR:2	L2R	CROSS	129-130	287-288	D000167	acriflavine	Chemical	129	130	3	D009369	tumor	Disease	287	288	9
7265370	Triamterene nephrolithiasis complicating dyazide therapy .|A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .|The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts .|Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed .	1:CID:2	L2R	NON-CROSS	0-1	1-2	D014223	Triamterene|triamterene|triamterene|triamterene	Chemical	0:9:37:47	1:10:38:48	0:1:2:3	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	L2R	NON-CROSS	25-26	37-38	D014223	Triamterene|triamterene|triamterene|triamterene	Chemical	0:9:37:47	1:10:38:48	0:1:2:3	D006973	hypertension	Disease	25	26	1	1:NR:2	R2L	NON-CROSS	3-4	1-2	C020743	dyazide|hydrochlorothiazide - triamterene	Chemical	3:20	4:23	0:1	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	R2L	CROSS	48-49	41-44	D014527	uric acid salts	Chemical	41	44	2	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	R2L	CROSS	48-49	41-44	D012492	uric acid salts	Chemical	41	44	2	D053040	nephrolithiasis|nephrolithiasis|nephrolithiasis	Disease	1:10:48	2:11:49	0:1:3	1:NR:2	L2R	NON-CROSS	20-23	25-26	C020743	dyazide|hydrochlorothiazide - triamterene	Chemical	3:20	4:23	0:1	D006973	hypertension	Disease	25	26	1	1:NR:2	R2L	CROSS	41-44	25-26	D014527	uric acid salts	Chemical	41	44	2	D006973	hypertension	Disease	25	26	1	1:NR:2	R2L	CROSS	41-44	25-26	D012492	uric acid salts	Chemical	41	44	2	D006973	hypertension	Disease	25	26	1
7423039	Metabolic involvement in adriamycin cardiotoxicity .|The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system .|Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture .|A possible involvement of energy metabolism was suggested previously , and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin - treated cells .|The adenylate energy charge was found to be significantly decreased , while the phophorylcreatine mole fraction was unchanged .|Such disparity suggests an inhibition of creatine phosphokinase .|The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool .|In the adriamycin - treated cells , the addition of adenosine increased the adenylate charge and , concomitant with this inrcease , the cells ' functional integrity , in terms of percentage of beating cells and rate of contractions , was maintained .	1:CID:2	L2R	NON-CROSS	3-4	4-5	D004317	adriamycin|adriamycin|Adriamycin|adriamycin|adriamycin	Chemical	3:10:24:65:127	4:11:25:66:128	0:1:2:3:7	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	58-59	7-8	D010725	phosphorylcreatine|phophorylcreatine	Chemical	58:83	59:84	3:4	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	95-96	7-8	D003401	creatine	Chemical	95	96	5	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	103-104	7-8	D000241	adenosine|adenosine	Chemical	103:135	104:136	6:7	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1	1:NR:2	R2L	CROSS	112-113	7-8	D000255	ATP|ATP	Chemical	112:122	113:123	6:6	D066126	cardiotoxicity|cardiotoxic	Disease	4:7	5:8	0:1
7444978	Age - dependent sensitivity of the rat to neurotoxic effects of streptomycin .|Streptomycin sulfate ( 300 mg / kg s . c . ) was injected for various periods into preweanling rats and for 3 weeks into weanling rats .|Beginning at 8 days of age , body movement and hearing were examined for 6 and up to 17 weeks , respectively .|Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to streptomycin than the site ( vestibular or central ) responsible for the dyskinesias .	1:CID:2	L2R	NON-CROSS	112-113	124-125	D013307	streptomycin|Streptomycin|streptomycin	Chemical	11:13:112	12:14:113	0:1:3	D004409	Abnormal movements|dyskinesias	Disease	64:124	66:125	3:3	1:CID:2	L2R	NON-CROSS	67-68	112-113	D013307	streptomycin|Streptomycin|streptomycin	Chemical	11:13:112	12:14:113	0:1:3	D003638	deafness	Disease	67	68	3	not_include	R2L	NON-CROSS	11-12	8-9	D013307	streptomycin|Streptomycin|streptomycin	Chemical	11:13:112	12:14:113	0:1:3	D020258	neurotoxic	Disease	8	9	0
7834920	Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis .|This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease .|This patient underwent a 10 - month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .|Renal biopsy revealed severe glomerulonephritis with crescents , electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate .|Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out .|This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin .	1:CID:2	R2L	NON-CROSS	6-7	2-3	D012293	rifampin|rifampin|rifampin|rifampin	Chemical	6:29:50:125	7:30:51:126	0:1:2:5	D005921	glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis	Disease	2:23:78:98:114:119	3:24:79:99:115:120	0:1:3:4:5:5	1:CID:2	L2R	NON-CROSS	50-51	65-67	D012293	rifampin|rifampin|rifampin|rifampin	Chemical	6:29:50:125	7:30:51:126	0:1:2:5	D051437	renal failure	Disease	65	67	2	1:NR:2	R2L	CROSS	78-79	52-53	D007538	isoniazid	Chemical	52	53	2	D005921	glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis|glomerulonephritis	Disease	2:23:78:98:114:119	3:24:79:99:115:120	0:1:3:4:5:5	1:NR:2	L2R	NON-CROSS	6-7	9-11	D012293	rifampin|rifampin|rifampin|rifampin	Chemical	6:29:50:125	7:30:51:126	0:1:2:5	D014397	pulmonary tuberculosis|pulmonary tuberculosis	Disease	9:54	11:56	0:2	1:NR:2	R2L	NON-CROSS	54-56	52-53	D007538	isoniazid	Chemical	52	53	2	D014397	pulmonary tuberculosis|pulmonary tuberculosis	Disease	9:54	11:56	0:2	1:NR:2	L2R	NON-CROSS	52-53	65-67	D007538	isoniazid	Chemical	52	53	2	D051437	renal failure	Disease	65	67	2
7881871	Time course of lipid peroxidation in puromycin aminonucleoside - induced nephropathy .|Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the proteinuria .|The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study .|Rats were treated with a single IV injection of puromycin aminonucleoside , ( PAN , 7 . 5 mg / kg ) and 24 hour urine samples were obtained prior to sacrifice on days 3 , 5 , 7 , 10 , 17 , 27 , 41 ( N = 5 - 10 per group ) .|The kidneys were removed , flushed with ice cold TRIS buffer .|Kidney cortices from each animal were used to prepare homogenates .|Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances .|Proteinuria was evident at day 5 , peaked at day 7 and persisted to day 27 .|Lipid peroxidation in homogenates was maximal at day 3 and declined rapidly to control levels by day 17 .|This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy .	1:CID:2	L2R	NON-CROSS	208-209	209-210	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|puromycin aminonucleoside|PAN|PAN	Chemical	6:23:26:65:69:208	8:25:27:67:70:209	0:1:1:3:3:9	D007674	nephropathy|nephropathy|nephropathy	Disease	10:30:209	11:31:210	0:1:9	1:CID:2	L2R	NON-CROSS	205-207	208-209	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|puromycin aminonucleoside|PAN|PAN	Chemical	6:23:26:65:69:208	8:25:27:67:70:209	0:1:1:3:3:9	D011507	proteinuria|proteinuria|Proteinuria|proteinuric injury	Disease	37:49:158:205	38:50:159:207	1:2:7:9	1:NR:2	R2L	NON-CROSS	13-14	10-11	D010100	oxygen	Chemical	13	14	1	D007674	nephropathy|nephropathy|nephropathy	Disease	10:30:209	11:31:210	0:1:9	1:NR:2	R2L	CROSS	209-210	153-155	C029684	thiobarbituric acid	Chemical	153	155	6	D007674	nephropathy|nephropathy|nephropathy	Disease	10:30:209	11:31:210	0:1:9	1:NR:2	L2R	NON-CROSS	13-14	37-38	D010100	oxygen	Chemical	13	14	1	D011507	proteinuria|proteinuria|Proteinuria|proteinuric injury	Disease	37:49:158:205	38:50:159:207	1:2:7:9	1:NR:2	R2L	CROSS	158-159	153-155	C029684	thiobarbituric acid	Chemical	153	155	6	D011507	proteinuria|proteinuria|Proteinuria|proteinuric injury	Disease	37:49:158:205	38:50:159:207	1:2:7:9
7930386	Clomipramine - induced sleep disturbance does not impair its prolactin - releasing action .|The present study was undertaken to examine the role of sleep disturbance , induced by clomipramine administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .|Two groups of supine subjects were studied under placebo - controlled conditions , one during the night , when sleeping ( n = 7 ) and the other at daytime , when awake ( n = 6 ) .|Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection .|Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure .|For both experiments the drug intake led to significant increases in PRL secretion , acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values .|During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness .|As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies ( 46 + / - 19 % vs 34 + / - 10 % ) , it can be concluded that the observed sleep disturbance did not interfere with the drug action per se .|The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency , as , for both , mean nocturnal values were similar with and without prior clomipramine ingestion .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D002997	Clomipramine|clomipramine|clomipramine|clomipramine|clomipramine	Chemical	0:29:97:161:278	1:30:98:162:279	0:1:3:6:8	D012893	sleep disturbance|sleep disturbance|sleep disturbance	Disease	3:24:231	5:26:233	0:1:7
7988234	Angioedema following the intravenous administration of metoprolol .|A 72 - year - old woman was admitted to the hospital with " flash " pulmonary edema , preceded by chest pain , requiring intubation .|Her medical history included coronary artery disease with previous myocardial infarctions , hypertension , and diabetes mellitus .|A history of angioedema secondary to lisinopril therapy was elicited .|Current medications did not include angiotensin - converting enzyme inhibitors or beta - blockers .|She had no previous beta - blocking drug exposure .|During the first day of hospitalization ( while intubated ) , intravenous metoprolol was given , resulting in severe angioedema .|The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride .	1:CID:2	R2L	NON-CROSS	6-7	0-1	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:CID:2	R2L	NON-CROSS	59-60	56-57	D017706	lisinopril	Chemical	59	60	3	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	R2L	CROSS	69-70	56-57	D000809	angiotensin	Chemical	69	70	4	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	R2L	NON-CROSS	117-118	111-112	D013256	steroids	Chemical	117	118	7	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	R2L	NON-CROSS	119-120	111-112	D004155	diphenhydramine	Chemical	119	120	7	D000799	Angioedema|angioedema|angioedema|angioedema	Disease	0:56:108:111	1:57:109:112	0:3:6:7	1:NR:2	L2R	CROSS	6-7	24-26	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	L2R	CROSS	6-7	29-31	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D002637	chest pain	Disease	29	31	1	1:NR:2	L2R	CROSS	6-7	39-42	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	L2R	CROSS	6-7	44-46	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	L2R	CROSS	6-7	47-48	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D006973	hypertension	Disease	47	48	2	1:NR:2	L2R	CROSS	6-7	50-52	D008790	metoprolol|metoprolol	Chemical	6:101	7:102	0:6	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	59-60	24-26	D017706	lisinopril	Chemical	59	60	3	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	69-70	24-26	D000809	angiotensin	Chemical	69	70	4	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	117-118	24-26	D013256	steroids	Chemical	117	118	7	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	119-120	24-26	D004155	diphenhydramine	Chemical	119	120	7	D011654	pulmonary edema	Disease	24	26	1	1:NR:2	R2L	CROSS	59-60	29-31	D017706	lisinopril	Chemical	59	60	3	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	69-70	29-31	D000809	angiotensin	Chemical	69	70	4	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	117-118	29-31	D013256	steroids	Chemical	117	118	7	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	119-120	29-31	D004155	diphenhydramine	Chemical	119	120	7	D002637	chest pain	Disease	29	31	1	1:NR:2	R2L	CROSS	59-60	39-42	D017706	lisinopril	Chemical	59	60	3	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	69-70	39-42	D000809	angiotensin	Chemical	69	70	4	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	117-118	39-42	D013256	steroids	Chemical	117	118	7	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	119-120	39-42	D004155	diphenhydramine	Chemical	119	120	7	D003324	coronary artery disease	Disease	39	42	2	1:NR:2	R2L	CROSS	59-60	44-46	D017706	lisinopril	Chemical	59	60	3	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	69-70	44-46	D000809	angiotensin	Chemical	69	70	4	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	117-118	44-46	D013256	steroids	Chemical	117	118	7	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	119-120	44-46	D004155	diphenhydramine	Chemical	119	120	7	D009203	myocardial infarctions	Disease	44	46	2	1:NR:2	R2L	CROSS	59-60	47-48	D017706	lisinopril	Chemical	59	60	3	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	69-70	47-48	D000809	angiotensin	Chemical	69	70	4	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	117-118	47-48	D013256	steroids	Chemical	117	118	7	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	119-120	47-48	D004155	diphenhydramine	Chemical	119	120	7	D006973	hypertension	Disease	47	48	2	1:NR:2	R2L	CROSS	59-60	50-52	D017706	lisinopril	Chemical	59	60	3	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	69-70	50-52	D000809	angiotensin	Chemical	69	70	4	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	117-118	50-52	D013256	steroids	Chemical	117	118	7	D003920	diabetes mellitus	Disease	50	52	2	1:NR:2	R2L	CROSS	119-120	50-52	D004155	diphenhydramine	Chemical	119	120	7	D003920	diabetes mellitus	Disease	50	52	2
8073369	Effect of coniine on the developing chick embryo .|Coniine , an alkaloid from Conium maculatum ( poison hemlock ) , has been shown to be teratogenic in livestock .|The major teratogenic outcome is arthrogryposis , presumably due to nicotinic receptor blockade .|However , coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits .|The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick .|Concentrations of coniine and nicotine sulfate were 0 . 015 % , 0 . 03 % , 0 . 075 % , 0 . 15 % , 0 . 75 % , 1 . 5 % , 3 % , and 6 % and 1 % , 5 % , and 10 % , respectively .|Both compounds caused deformations and lethality in a dose - dependent manner .|All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0 . 75 % .|The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes .|No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive cranial hemorrhage occurred in all nicotine sulfate - treated chicks .|There was a statistically significant ( P < or = 0 . 01 ) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound .|Control chicks were in motion an average of 33 . 67 % of the time , while coniine - treated chicks were only moving 8 . 95 % of a 5 - min interval , and no movement was observed for nicotine sulfate treated chicks .|In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .|Data from this model support a mechanism involving nicotinic receptor blockade with subsequent decreased fetal movement .	1:CID:2	L2R	NON-CROSS	322-323	325-326	C007112	coniine|Coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine	Chemical	2:9:46:77:87:168:181:250:278:322	3:10:47:78:88:169:182:251:279:323	0:1:3:4:5:7:8:10:11:12	D001176	arthrogryposis|arthrogryposis|arthrogryposis	Disease	35:51:325	36:52:326	2:3:12	1:CID:2	R2L	CROSS	325-326	302-303	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	79:89:157:183:226:252:302	80:90:158:184:227:253:303	4:5:7:8:9:10:11	D001176	arthrogryposis|arthrogryposis|arthrogryposis	Disease	35:51:325	36:52:326	2:3:12	1:CID:2	L2R	NON-CROSS	221-223	226-227	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	79:89:157:183:226:252:302	80:90:158:184:227:253:303	4:5:7:8:9:10:11	D002543	cranial hemorrhage	Disease	221	223	9	not_include	L2R	NON-CROSS	177-178	181-182	C007112	coniine|Coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine	Chemical	2:9:46:77:87:168:181:250:278:322	3:10:47:78:88:169:182:251:279:323	0:1:3:4:5:7:8:10:11:12	D009140	deformations|deformations|excessive flexion or extension of one or more toes	Disease	144:177:186	145:178:195	6:8:8	1:NR:2	L2R	CROSS	221-223	250-251	C007112	coniine|Coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine|coniine	Chemical	2:9:46:77:87:168:181:250:278:322	3:10:47:78:88:169:182:251:279:323	0:1:3:4:5:7:8:10:11:12	D002543	cranial hemorrhage	Disease	221	223	9	not_include	L2R	NON-CROSS	183-184	186-195	D009538	nicotine|nicotine|nicotine|nicotine|nicotine|nicotine|nicotine	Chemical	79:89:157:183:226:252:302	80:90:158:184:227:253:303	4:5:7:8:9:10:11	D009140	deformations|deformations|excessive flexion or extension of one or more toes	Disease	144:177:186	145:178:195	6:8:8
8302922	Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension .|To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced hypotension on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .|An initial dose of 0 . 1 microgram . kg - 1 . min - 1 of PGE1 ( 15 patients ) , or 10 micrograms . kg - 1 . min - 1 of TMP ( 15 patients ) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure ( MAP ) at about 60 mmHg .|The hypotensive drug was discontinued at the completion of the operative procedure .|After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation .|Heart rate ( HR ) did not change in either group .|EBFF did not change during PGE1 infusion whereas in the TMP group , EBF decreased significantly at 30 and 60 min after the start of TMP ( preinfusion : 45 . 9 + / - 13 . 9 ml / 100g / min .|30 min : 32 . 3 + / - 9 . 9 ml / 100 g / min ( P < 0 . 05 ) .|60 min : 30 + / - 7 . 5 ml / 100 g / min ( P < 0 . 05 ) ) .|These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF .	1:CID:2	L2R	NON-CROSS	173-174	176-177	D000527	prostaglandin E1|prostaglandin E1|PGE1|PGE1|PGE1|PGE1|PGE1|PGE1	Chemical	4:16:19:78:143:176:203:297	6:18:20:79:144:177:204:298	0:1:1:2:4:4:6:9	D007022	hypotension|hypotension|hypotensive|hypotension|hypotensive	Disease	9:27:129:173:304	10:28:130:174:305	0:1:3:4:9	1:CID:2	L2R	NON-CROSS	7-8	9-10	D014294	trimethaphan|trimethaphan|TMP|TMP|TMP|TMP|TMP|TMP|TMP	Chemical	7:22:24:96:145:208:223:302:310	8:23:25:97:146:209:224:303:311	0:1:1:2:4:6:6:9:9	D007022	hypotension|hypotension|hypotensive|hypotension|hypotensive	Disease	9:27:129:173:304	10:28:130:174:305	0:1:3:4:9	1:NR:2	R2L	NON-CROSS	58-59	27-28	D007530	isoflurane	Chemical	58	59	1	D007022	hypotension|hypotension|hypotensive|hypotension|hypotensive	Disease	9:27:129:173:304	10:28:130:174:305	0:1:3:4:9
8410052	Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat .|Immunohistochemistry with monoclonal antibodies against neurofilament ( NF ) proteins of middle and high molecular weight class , NF - M and NF - H , was used to study axonal injury in the borderzone of focal lesions in rats .|Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion .|Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine - induced status epilepticus .|Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions .|Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state .|These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions .	1:CID:2	R2L	CROSS	90-91	59-63	D010862	pilocarpine	Chemical	90	91	3	D001480	axonal damage|axonal injury|injury in the cortex|axonal damage	Disease	8:47:59:145	10:49:63:147	0:1:2:6	1:CID:2	R2L	NON-CROSS	90-91	80-86	D010862	pilocarpine	Chemical	90	91	3	D002544	Infarcts in substantia nigra pars reticulata	Disease	80	86	3	1:CID:2	L2R	NON-CROSS	90-91	93-95	D010862	pilocarpine	Chemical	90	91	3	D013226	status epilepticus	Disease	93	95	3	1:NR:2	R2L	NON-CROSS	68-69	59-63	D019344	lactate	Chemical	68	69	2	D001480	axonal damage|axonal injury|injury in the cortex|axonal damage	Disease	8:47:59:145	10:49:63:147	0:1:2:6	1:NR:2	L2R	CROSS	68-69	80-86	D019344	lactate	Chemical	68	69	2	D002544	Infarcts in substantia nigra pars reticulata	Disease	80	86	3	1:NR:2	L2R	CROSS	68-69	93-95	D019344	lactate	Chemical	68	69	2	D013226	status epilepticus	Disease	93	95	3	1:NR:2	L2R	CROSS	68-69	150-151	D019344	lactate	Chemical	68	69	2	D014947	traumatic	Disease	150	151	6	1:NR:2	L2R	CROSS	90-91	150-151	D010862	pilocarpine	Chemical	90	91	3	D014947	traumatic	Disease	150	151	6
8423889	Increase of Parkinson disability after fluoxetine medication .|Depression is a major clinical feature of Parkinson 's disease .|We report the increased amount of motor disability in four patients with idiopathic Parkinson 's disease after exposure to the antidepressant fluoxetine .|The possibility of a clinically relevant dopamine - antagonistic capacity of fluoxetine in Parkinson 's disease patients must be considered .	1:CID:2	R2L	NON-CROSS	5-6	2-4	D005473	fluoxetine|fluoxetine|fluoxetine	Chemical	5:40:53	6:41:54	0:2:3	D009069	Parkinson disability|motor disability	Disease	2:25	4:27	0:2	1:NR:2	R2L	NON-CROSS	39-40	25-27	D000928	antidepressant	Chemical	39	40	2	D009069	Parkinson disability|motor disability	Disease	2:25	4:27	0:2	1:NR:2	R2L	CROSS	48-49	25-27	D004298	dopamine	Chemical	48	49	3	D009069	Parkinson disability|motor disability	Disease	2:25	4:27	0:2	1:NR:2	L2R	CROSS	5-6	8-9	D005473	fluoxetine|fluoxetine|fluoxetine	Chemical	5:40:53	6:41:54	0:2:3	D003866	Depression	Disease	8	9	1	1:NR:2	L2R	NON-CROSS	53-54	55-58	D005473	fluoxetine|fluoxetine|fluoxetine	Chemical	5:40:53	6:41:54	0:2:3	D010300	Parkinson 's disease|idiopathic Parkinson 's disease|Parkinson 's disease	Disease	15:31:55	18:35:58	1:2:3	1:NR:2	R2L	CROSS	39-40	8-9	D000928	antidepressant	Chemical	39	40	2	D003866	Depression	Disease	8	9	1	1:NR:2	R2L	CROSS	48-49	8-9	D004298	dopamine	Chemical	48	49	3	D003866	Depression	Disease	8	9	1	1:NR:2	R2L	NON-CROSS	39-40	31-35	D000928	antidepressant	Chemical	39	40	2	D010300	Parkinson 's disease|idiopathic Parkinson 's disease|Parkinson 's disease	Disease	15:31:55	18:35:58	1:2:3	1:NR:2	R2L	NON-CROSS	55-58	48-49	D004298	dopamine	Chemical	48	49	3	D010300	Parkinson 's disease|idiopathic Parkinson 's disease|Parkinson 's disease	Disease	15:31:55	18:35:58	1:2:3
8682684	Acetaminophen - induced hypotension .|Through 30 years of widespread use , acetaminophen has been shown to be a remarkably safe medication in therapeutic dosages .|The potential for acetaminophen to produce cardiovascular toxicities is very low .|However , acetaminophen has been demonstrated to produce symptoms of anaphylaxis , including hypotension , in sensitive individuals .|This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen .|Other symptoms of allergic reactions were not clinically detectable .|The hypotensive episodes were severe enough to require vasopressor administration .|The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D007022	hypotension|hypotension|hypotension|hypotensive|hypotension	Disease	3:51:69:88:111	4:52:70:89:112	0:3:4:6:7	not_include	L2R	NON-CROSS	29-30	32-34	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D002318	cardiovascular toxicities	Disease	32	34	2	1:NR:2	L2R	NON-CROSS	40-41	48-49	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D000707	anaphylaxis	Disease	48	49	3	1:NR:2	L2R	NON-CROSS	61-63	75-76	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D016638	critically ill	Disease	61	63	4	1:NR:2	L2R	CROSS	75-76	80-82	D000082	Acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen|acetaminophen	Chemical	0:12:29:40:75:107	1:13:30:41:76:108	0:1:2:3:4:7	D004342	allergic reactions	Disease	80	82	5
9625142	Acute hepatitis , autoimmune hemolytic anemia , and erythroblastocytopenia induced by ceftriaxone .|An 80 - yr - old man developed acute hepatitis shortly after ingesting oral ceftriaxone .|Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia .|These responded to systemic steroids and immunoglobulins .|Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics .	1:CID:2	R2L	NON-CROSS	27-28	22-23	D002443	ceftriaxone|ceftriaxone	Chemical	11:27	12:28	0:1	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:CID:2	R2L	NON-CROSS	11-12	3-6	D002443	ceftriaxone|ceftriaxone	Chemical	11:27	12:28	0:1	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2	1:NR:2	R2L	CROSS	39-41	22-23	D047090	beta lactam|beta lactam	Chemical	39:94	41:96	2:4	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:NR:2	R2L	CROSS	50-51	22-23	D001663	bilirubin	Chemical	50	51	2	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:NR:2	R2L	CROSS	70-71	22-23	D013256	steroids	Chemical	70	71	3	D056486	hepatitis|hepatitis	Disease	1:22	2:23	0:1	1:NR:2	R2L	NON-CROSS	60-63	39-41	D047090	beta lactam|beta lactam	Chemical	39:94	41:96	2:4	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2	1:NR:2	R2L	NON-CROSS	60-63	50-51	D001663	bilirubin	Chemical	50	51	2	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2	1:NR:2	R2L	CROSS	70-71	60-63	D013256	steroids	Chemical	70	71	3	D000744	autoimmune hemolytic anemia|autoimmune hemolytic anemia	Disease	3:60	6:63	0:2
9766615	Adverse effects of the atypical antipsychotics .|Collaborative Working Group on Clinical Trial Evaluations .|Adverse effects of antipsychotics often lead to noncompliance .|Thus , clinicians should address patients ' concerns about adverse effects and attempt to choose medications that will improve their patients ' quality of life as well as overall health .|The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics .|Conventional agents are associated with unwanted central nervous system effects , including extrapyramidal symptoms ( EPS ) , tardive dyskinesia , sedation , and possible impairment of some cognitive measures , as well as cardiac effects , orthostatic hypotension , hepatic changes , anticholinergic side effects , sexual dysfunction , and weight gain .|The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( clozapine only ) .|Since the incidence and severity of specific adverse effects differ among the various atypicals , the clinician should carefully consider which side effects are most likely to lead to the individual 's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient .	1:CID:2	L2R	NON-CROSS	171-172	173-174	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D000380	agranulocytosis	Disease	171	172	6	1:NR:2	R2L	NON-CROSS	167-168	136-137	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D001480	extrapyramidal symptoms|EPS|EPS	Disease	85:88:136	87:89:137	5:5:6	1:NR:2	R2L	CROSS	167-168	91-93	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D004409	tardive dyskinesia	Disease	91	93	5	1:NR:2	R2L	CROSS	167-168	110-112	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D007024	orthostatic hypotension	Disease	110	112	5	1:NR:2	R2L	NON-CROSS	167-168	156-158	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D012735	sexual dysfunction|sexual dysfunction	Disease	120:156	122:158	5:6	1:NR:2	R2L	NON-CROSS	167-168	153-155	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D015430	weight gain|weight gain	Disease	124:153	126:155	5:6	1:NR:2	R2L	NON-CROSS	167-168	163-164	D003024	clozapine|clozapine	Chemical	167:173	168:174	6:6	D012640	seizure	Disease	163	164	6
10193204	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation .|Tetrandrine ( TET ) and fangchinoline ( FAN ) are two naturally occurring analogues with a bisbenzylisoquinoline structure .|The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .|In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of thrombosis by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .|In the vitro human platelet aggregations induced by the agonists used in tests , TET and FAN showed the inhibitions dose dependently .|In addition , neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time ( APTT ) , prothrombin time ( PT ) and thrombin time ( TT ) using human - citrated plasma .|These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities .	1:CID:2	R2L	NON-CROSS	55-56	50-51	D004837	epinephrine|EP	Chemical	55:57	56:58	2:2	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	L2R	NON-CROSS	2-3	7-8	C009438	tetrandrine|Tetrandrine|TET|TET|TET|TET|TET|TET	Chemical	2:15:17:44:91:151:164:207	3:16:18:45:92:152:165:208	0:1:1:2:3:4:5:6	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	L2R	NON-CROSS	12-14	15-16	C009438	tetrandrine|Tetrandrine|TET|TET|TET|TET|TET|TET	Chemical	2:15:17:44:91:151:164:207	3:16:18:45:92:152:165:208	0:1:1:2:3:4:5:6	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	L2R	NON-CROSS	44-45	66-68	C009438	tetrandrine|Tetrandrine|TET|TET|TET|TET|TET|TET	Chemical	2:15:17:44:91:151:164:207	3:16:18:45:92:152:165:208	0:1:1:2:3:4:5:6	D001778	blood coagulation	Disease	66	68	2	1:NR:2	L2R	NON-CROSS	4-5	7-8	C060802	fangchinoline|fangchinoline|FAN|FAN|FAN|FAN|FAN|FAN	Chemical	4:20:22:46:93:153:166:209	5:21:23:47:94:154:167:210	0:1:1:2:3:4:5:6	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	L2R	NON-CROSS	12-14	20-21	C060802	fangchinoline|fangchinoline|FAN|FAN|FAN|FAN|FAN|FAN	Chemical	4:20:22:46:93:153:166:209	5:21:23:47:94:154:167:210	0:1:1:2:3:4:5:6	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	L2R	NON-CROSS	46-47	66-68	C060802	fangchinoline|fangchinoline|FAN|FAN|FAN|FAN|FAN|FAN	Chemical	4:20:22:46:93:153:166:209	5:21:23:47:94:154:167:210	0:1:1:2:3:4:5:6	D001778	blood coagulation	Disease	66	68	2	1:NR:2	R2L	CROSS	50-51	31-32	D044182	bisbenzylisoquinoline	Chemical	31	32	1	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	R2L	NON-CROSS	111-113	100-101	D001241	acetylsalicylic acid|ASA	Chemical	111:114	113:115	3:3	D013927	thrombosis|thrombosis|thrombosis	Disease	7:50:100	8:51:101	0:2:3	1:NR:2	R2L	CROSS	31-32	12-14	D044182	bisbenzylisoquinoline	Chemical	31	32	1	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	R2L	NON-CROSS	63-65	57-58	D004837	epinephrine|EP	Chemical	55:57	56:58	2:2	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	R2L	CROSS	141-143	114-115	D001241	acetylsalicylic acid|ASA	Chemical	111:114	113:115	3:3	D001791	platelet aggregation|platelet aggregation|platelet aggregations	Disease	12:63:141	14:65:143	0:2:4	1:NR:2	L2R	CROSS	31-32	66-68	D044182	bisbenzylisoquinoline	Chemical	31	32	1	D001778	blood coagulation	Disease	66	68	2	1:NR:2	L2R	NON-CROSS	57-58	66-68	D004837	epinephrine|EP	Chemical	55:57	56:58	2:2	D001778	blood coagulation	Disease	66	68	2	1:NR:2	R2L	CROSS	111-113	66-68	D001241	acetylsalicylic acid|ASA	Chemical	111:114	113:115	3:3	D001778	blood coagulation	Disease	66	68	2
10526274	Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who can not receive cisplatin .|Oncopaz Cooperative Group .|BACKGROUND : Although the prevalence of nonsmall cell lung carcinoma ( NSCLC ) is high among elderly patients , few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients .|Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable toxicity and improvement in symptoms and quality of life .|In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .|METHODS : Forty - nine patients with advanced NSCLC were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin .|All patients were evaluable for response and toxicity .|Treatment was comprised of VNB , 25 mg / m ( 2 ) , plus GEM , 1000 mg / m ( 2 ) , both on Days 1 , 8 , and 15 every 28 days .|Patients received a minimum of three courses unless progressive disease was detected .|RESULTS : One hundred sixty - five courses were administered , with a median of 3 .|6 courses per patient .|The overall response rate was 26 % ( 95 % confidence interval , 15 - 41 % ) .|Two patients attained a complete response ( 4 % ) and 11 patients ( 22 % ) achieved a partial response .|Eastern Cooperative Oncology Group performance status improved in 35 % of those patients with an initial value > 0 , whereas relief of at least 1 symptom without worsening of other symptoms was noted in 27 patients ( 55 % ) .|The median time to progression was 16 weeks and the 1 - year survival rate was 33 % .|Toxicity was mild .|Six patients ( 12 % ) had World Health Organization Grade 3 - 4 neutropenia , 2 patients ( 4 % ) had Grade 3 - 4 thrombocytopenia , and 2 patients ( 4 % ) had Grade 3 neurotoxicity .|Three patients with severe neutropenia ( 6 % ) died of sepsis .|The median age of those patients developing Grade 3 - 4 neutropenia was significantly higher than that of the remaining patients ( 75 years vs . 72 years ; P = 0 . 047 ) .|CONCLUSIONS : The combination of GEM and VNB is moderately active and well tolerated except in patients age > / = 75 years .|This age group had an increased risk of myelosuppression .|Therefore the prophylactic use of granulocyte - colony stimulating factor should be considered with this treatment .|New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC .	1:CID:2	L2R	CROSS	428-429	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D009503	neutropenia|neutropenia|neutropenia	Disease	377:408:428	378:409:429	16:17:18	1:CID:2	L2R	CROSS	390-391	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D013921	thrombocytopenia	Disease	390	391	16	1:CID:2	L2R	CROSS	402-403	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D020258	neurotoxicity	Disease	402	403	16	1:CID:2	L2R	CROSS	428-429	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D009503	neutropenia|neutropenia|neutropenia	Disease	377:408:428	378:409:429	16:17:18	1:CID:2	L2R	CROSS	390-391	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D013921	thrombocytopenia	Disease	390	391	16	1:CID:2	L2R	CROSS	402-403	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D020258	neurotoxicity	Disease	402	403	16	1:NR:2	L2R	NON-CROSS	0-1	4-8	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D002289	nonsmall cell lung carcinoma|nonsmall cell lung carcinoma|NSCLC|NSCLC|NSCLC|NSCLC	Disease	4:32:37:125:145:520	8:36:38:126:146:521	0:2:2:4:5:22	1:NR:2	L2R	NON-CROSS	112-113	117-118	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D064420	toxicity|toxicity|toxicity|toxicity|Toxicity|toxicity	Disease	53:95:112:182:359:512	54:96:113:183:360:513	2:3:4:6:15:22	1:NR:2	L2R	CROSS	415-416	458-459	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D018805	sepsis	Disease	415	416	17	1:NR:2	L2R	CROSS	458-459	485-486	C056507	Gemcitabine|gemcitabine|GEM|GEM|GEM|GEM	Chemical	0:75:77:117:199:458	1:76:78:118:200:459	0:3:3:4:7:19	D001855	myelosuppression	Disease	485	486	20	1:NR:2	L2R	NON-CROSS	2-3	4-8	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D002289	nonsmall cell lung carcinoma|nonsmall cell lung carcinoma|NSCLC|NSCLC|NSCLC|NSCLC	Disease	4:32:37:125:145:520	8:36:38:126:146:521	0:2:2:4:5:22	1:NR:2	L2R	NON-CROSS	182-183	188-189	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D064420	toxicity|toxicity|toxicity|toxicity|Toxicity|toxicity	Disease	53:95:112:182:359:512	54:96:113:183:360:513	2:3:4:6:15:22	1:NR:2	L2R	CROSS	415-416	460-461	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D018805	sepsis	Disease	415	416	17	1:NR:2	L2R	CROSS	460-461	485-486	C030852	vinorelbine|vinorelbine|VNB|VNB|VNB|VNB	Chemical	2:70:72:119:188:460	3:71:73:120:189:461	0:3:3:4:7:19	D001855	myelosuppression	Disease	485	486	20	1:NR:2	R2L	NON-CROSS	133-134	125-126	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D002289	nonsmall cell lung carcinoma|nonsmall cell lung carcinoma|NSCLC|NSCLC|NSCLC|NSCLC	Disease	4:32:37:125:145:520	8:36:38:126:146:521	0:2:2:4:5:22	1:NR:2	L2R	NON-CROSS	173-174	182-183	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D064420	toxicity|toxicity|toxicity|toxicity|Toxicity|toxicity	Disease	53:95:112:182:359:512	54:96:113:183:360:513	2:3:4:6:15:22	1:NR:2	L2R	CROSS	173-174	377-378	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D009503	neutropenia|neutropenia|neutropenia	Disease	377:408:428	378:409:429	16:17:18	1:NR:2	L2R	CROSS	173-174	390-391	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D013921	thrombocytopenia	Disease	390	391	16	1:NR:2	L2R	CROSS	173-174	402-403	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D020258	neurotoxicity	Disease	402	403	16	1:NR:2	L2R	CROSS	173-174	415-416	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D018805	sepsis	Disease	415	416	17	1:NR:2	L2R	CROSS	173-174	485-486	D002945	cisplatin|cisplatin|cisplatin	Chemical	20:133:173	21:134:174	0:4:5	D001855	myelosuppression	Disease	485	486	20
10669626	Warfarin - induced artery calcification is accelerated by growth and vitamin D .|The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .|The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin - treated rats .|Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .|In contrast , no artery calcification could be detected in 10 - month - old adult rats even after 4 weeks of Warfarin treatment .|To directly examine the importance of growth to Warfarin - induced artery calcification in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .|Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .|Although the explanation for the association between artery calcification and growth status can not be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .|This observation suggests that increased susceptibility to Warfarin - induced artery calcification could be related to higher serum phosphate levels .|The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification .|High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days .|High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media , but at treatment times of 2 weeks or longer yet not at 1 week .|In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D - treated rats at 3 and 4 days .|There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .|Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor .|High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .|These observations indicate that although the gamma - carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at calcification sites .	1:CID:2	L2R	NON-CROSS	358-359	360-362	D014859	Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin	Chemical	0:35:81:91:142:153:204:297:331:358:393:437:506:525:537:570	1:36:82:92:143:154:205:298:332:359:394:438:507:526:538:571	0:1:2:3:4:5:6:7:8:9:11:12:14:14:14:15	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	not_include	L2R	NON-CROSS	437-438	444-445	D014859	Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin|Warfarin	Chemical	0:35:81:91:142:153:204:297:331:358:393:437:506:525:537:570	1:36:82:92:143:154:205:298:332:359:394:438:507:526:538:571	0:1:2:3:4:5:6:7:8:9:11:12:14:14:14:15	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	NON-CROSS	496-498	492-494	D014807	vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D	Chemical	10:20:355:366:449:469:479:492:519:527:567	12:22:357:368:451:471:481:494:521:529:569	0:1:9:10:12:13:13:13:14:14:15	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	268-270	264-265	D010710	phosphate|phosphate|phosphate	Chemical	264:278:342	265:279:343	7:7:8	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	399-403	390-392	D014812	vitamin K	Chemical	390	392	11	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	503-504	496-498	D002118	calcium|calcium|calcium	Chemical	487:503:516	488:504:517	13:13:14	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	R2L	NON-CROSS	584-587	561-563	D015055	gamma - carboxylated|gamma - carboxyglutamate	Chemical	584:594	587:597	15:16	D061205	artery calcification|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|calcification of the artery|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|artery calcification|calcification of the artery|calcification of the artery|artery calcification|artery calcification|artery calcification	Disease	3:27:78:95:124:156:208:223:243:268:300:334:360:372:399:473:496:561	5:29:80:99:126:158:212:225:245:270:302:336:362:376:403:475:498:563	0:1:2:3:4:5:6:6:7:7:7:8:9:10:11:13:13:15	1:NR:2	L2R	NON-CROSS	444-445	449-451	D014807	vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D|vitamin D	Chemical	10:20:355:366:449:469:479:492:519:527:567	12:22:357:368:451:471:481:494:521:529:569	0:1:9:10:12:13:13:13:14:14:15	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	CROSS	444-445	342-343	D010710	phosphate|phosphate|phosphate	Chemical	264:278:342	265:279:343	7:7:8	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	CROSS	444-445	390-392	D014812	vitamin K	Chemical	390	392	11	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	NON-CROSS	547-548	516-517	D002118	calcium|calcium|calcium	Chemical	487:503:516	488:504:517	13:13:14	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16	1:NR:2	R2L	NON-CROSS	610-611	594-597	D015055	gamma - carboxylated|gamma - carboxyglutamate	Chemical	584:594	587:597	15:16	D002114	calcification|calcification|calcification|calcification|calcification|calcification	Disease	47:111:444:547:610:621	48:112:445:548:611:622	1:3:12:14:16:16
11379838	Antidepressant - induced mania in bipolar patients : identification of risk factors .|BACKGROUND : Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .|METHOD : The response of 44 patients meeting DSM - IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery - Asberg Depression Rating Scale and the Bech - Rafaelson Mania Rating Scale .|Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM - IV bipolar I vs . bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs . antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs . anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi - structured Affective Temperament Interview .|RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with SSRIs [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .|Sex , age , diagnosis ( bipolar I vs . bipolar II ) , and additional treatment did not affect the risk of switching .|The incidence of mood switches seemed not to differ between patients receiving an anticonvulsant and those receiving no mood stabilizer .|In contrast , mood switches were less frequent in patients receiving lithium ( 15 % , 4 / 26 ) than in patients not treated with lithium ( 44 % , 8 / 18 ; p = . 04 ) .|The number of previous manic episodes did not affect the probability of switching , whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching ( p = . 008 ) .|CONCLUSION : The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment .|Particular attention should be paid to patients with a hyperthymic temperament , who have a greater risk of mood switches .	1:CID:2	L2R	NON-CROSS	0-1	3-4	D000928	Antidepressant|antidepressants|antidepressant|antidepressant|antidepressant	Chemical	0:25:127:135:390	1:26:128:136:391	0:1:3:3:9	D001714	mania|bipolar|mania|bipolar depression|bipolar disorder|manic|hypomanic|DSM - IV bipolar I|bipolar II|manic|hypomania|mania|manic|hypomanic|bipolar I|bipolar II|manic	Disease	3:5:22:38:54:87:89:108:115:122:192:194:235:247:256:260:341	4:6:23:40:56:88:90:113:117:123:193:195:236:248:258:262:342	0:0:1:1:2:3:3:3:3:3:4:4:4:4:5:5:8	1:CID:2	R2L	NON-CROSS	235-236	219-220	D017367	serotonin reuptake inhibitors|SSRIs|SSRIs	Chemical	143:147:219	146:148:220	3:3:4	D001714	mania|bipolar|mania|bipolar depression|bipolar disorder|manic|hypomanic|DSM - IV bipolar I|bipolar II|manic|hypomania|mania|manic|hypomanic|bipolar I|bipolar II|manic	Disease	3:5:22:38:54:87:89:108:115:122:192:194:235:247:256:260:341	4:6:23:40:56:88:90:113:117:123:193:195:236:248:258:262:342	0:0:1:1:2:3:3:3:3:3:4:4:4:4:5:5:8	1:NR:2	R2L	NON-CROSS	341-342	322-323	D008094	lithium|lithium|lithium|lithium	Chemical	158:307:322:396	159:308:323:397	3:7:7:9	D001714	mania|bipolar|mania|bipolar depression|bipolar disorder|manic|hypomanic|DSM - IV bipolar I|bipolar II|manic|hypomania|mania|manic|hypomanic|bipolar I|bipolar II|manic	Disease	3:5:22:38:54:87:89:108:115:122:192:194:235:247:256:260:341	4:6:23:40:56:88:90:113:117:123:193:195:236:248:258:262:342	0:0:1:1:2:3:3:3:3:3:4:4:4:4:5:5:8
11419773	Caffeine - induced cardiac arrhythmia : an unrecognised danger of healthfood products .|We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a " natural energy " guarana health drink containing a high concentration of caffeine .|This case highlights the need for adequate labelling and regulation of such products .	1:CID:2	L2R	NON-CROSS	32-34	49-50	D002110	Caffeine|caffeine	Chemical	0:49	1:50	0:1	D014693	ventricular fibrillation	Disease	32	34	1	not_include	L2R	NON-CROSS	0-1	3-5	D002110	Caffeine|caffeine	Chemical	0:49	1:50	0:1	D001145	cardiac arrhythmia	Disease	3	5	0	1:NR:2	L2R	NON-CROSS	26-29	49-50	D002110	Caffeine|caffeine	Chemical	0:49	1:50	0:1	D008945	mitral valve prolapse	Disease	26	29	1
11581460	Bladder retention of urine as a result of continuous intravenous infusion of fentanyl : 2 case reports .|Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit , as well as to facilitate synchrony between ventilator and spontaneous breaths .|Fentanyl , an opioid analgesic , is frequently used in the neonatal intensive care unit setting for these very purposes .|Various reported side effects of fentanyl administration include chest wall rigidity , hypotension , respiratory depression , and bradycardia .|Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported .	1:CID:2	R2L	NON-CROSS	12-13	1-4	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D016055	retention of urine	Disease	1	4	0	1:CID:2	L2R	NON-CROSS	84-85	91-92	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D007022	hypotension	Disease	91	92	3	1:CID:2	L2R	NON-CROSS	84-85	93-95	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D012131	respiratory depression	Disease	93	95	3	1:CID:2	L2R	NON-CROSS	84-85	97-98	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D001919	bradycardia	Disease	97	98	3	1:CID:2	L2R	NON-CROSS	104-107	121-122	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D001745	urinary bladder retention	Disease	104	107	4	1:NR:2	L2R	CROSS	12-13	31-32	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D010146	pain	Disease	31	32	1	1:NR:2	L2R	NON-CROSS	84-85	87-90	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D009127	chest wall rigidity	Disease	87	90	3	1:NR:2	L2R	NON-CROSS	113-114	121-122	D005283	fentanyl|Fentanyl|fentanyl|fentanyl	Chemical	12:58:84:121	13:59:85:122	0:2:3:4	D006869	hydronephrosis	Disease	113	114	4
11706060	Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice .|Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .|To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic AIDS mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and indinavir or vehicle control for 10 days or 35 days .|At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of CM ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase [ SERCA2 ] ) , and determination of plasma LA .|Myocardial histologic features were analyzed semiquantitatively and results were confirmed by transmission electron microscopy .|After 35 days in the TG + HAART cohort , left ventricular mass increased 160 % by echocardiography .|Molecularly , ANF mRNA increased 250 % and SERCA2 mRNA decreased 57 % .|Biochemically , LA was elevated ( 8 . 5 + / - 2 . 0 mM ) .|Pathologically , granular cytoplasmic changes were found in cardiac myocytes , indicating enlarged , damaged mitochondria .|Findings were confirmed ultrastructurally .|No changes were found in other cohorts .|After 10 days , only ANF was elevated , and only in the TG + HAART cohort .|Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice .	1:CID:2	R2L	CROSS	120-121	87-88	D015215	zidovudine	Chemical	87	88	2	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:CID:2	R2L	CROSS	120-121	89-90	D019259	lamivudine	Chemical	89	90	2	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:CID:2	R2L	CROSS	120-121	92-93	D019469	indinavir	Chemical	92	93	2	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:NR:2	R2L	NON-CROSS	270-271	267-268	D019344	lactate|lactate|LA|LA|LA|LA	Chemical	8:32:34:144:196:270	9:33:35:145:197:271	0:1:1:3:7:12	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:NR:2	R2L	NON-CROSS	133-134	120-121	D002118	calcium	Chemical	133	134	3	D009202	cardiomyopathy|cardiomyopathy|CM|CM|CM	Disease	4:24:26:120:267	5:25:27:121:268	0:1:1:3:12	1:NR:2	L2R	NON-CROSS	270-271	272-273	D019344	lactate|lactate|LA|LA|LA|LA	Chemical	8:32:34:144:196:270	9:33:35:145:197:271	0:1:1:3:7:12	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	L2R	NON-CROSS	34-35	41-43	D019344	lactate|lactate|LA|LA|LA|LA	Chemical	8:32:34:144:196:270	9:33:35:145:197:271	0:1:1:3:7:12	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	NON-CROSS	87-88	60-61	D015215	zidovudine	Chemical	87	88	2	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	NON-CROSS	89-90	60-61	D019259	lamivudine	Chemical	89	90	2	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	NON-CROSS	92-93	60-61	D019469	indinavir	Chemical	92	93	2	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	CROSS	133-134	60-61	D002118	calcium	Chemical	133	134	3	D000163	AIDS|AIDS|AIDS|AIDS	Disease	11:37:60:272	12:38:61:273	0:1:2:12	1:NR:2	R2L	CROSS	87-88	41-43	D015215	zidovudine	Chemical	87	88	2	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	CROSS	89-90	41-43	D019259	lamivudine	Chemical	89	90	2	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	CROSS	92-93	41-43	D019469	indinavir	Chemical	92	93	2	D028361	mitochondrial dysfunction	Disease	41	43	1	1:NR:2	R2L	CROSS	133-134	41-43	D002118	calcium	Chemical	133	134	3	D028361	mitochondrial dysfunction	Disease	41	43	1
11752354	Oral contraceptives and the risk of myocardial infarction .|BACKGROUND : An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some , but not all , studies .|We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .|Subjects supplied information on oral - contraceptive use and major cardiovascular risk factors .|An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS : The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .|The adjusted odds ratio was 2 . 5 ( 95 percent confidence interval , 1 . 5 to 4 . 1 ) among women who used second - generation oral contraceptives and 1 . 3 ( 95 percent confidence interval , 0 . 7 to 2 . 5 ) among those who used third - generation oral contraceptives .|Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of myocardial infarction was increased among women who used second - generation oral contraceptives .|The results with respect to the use of third - generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second - generation oral contraceptives .|The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation .	1:CID:2	L2R	NON-CROSS	0-2	6-8	D003276	Oral contraceptives|oral contraceptives|oral contraceptives|oral - contraceptive|oral contraceptive|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives|oral contraceptives	Chemical	0:17:75:163:211:267:294:301:370:384:403:417	2:19:77:166:213:269:296:303:372:386:405:419	0:1:2:3:4:5:5:6:6:7:7:8	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	47-48	23-25	D011372	progestagen	Chemical	47	48	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	59-60	23-25	D017135	desogestrel	Chemical	59	60	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	61-62	23-25	C033273	gestodene	Chemical	61	62	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	73-74	23-25	D016912	levonorgestrel	Chemical	73	74	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8	1:NR:2	R2L	NON-CROSS	123-125	81-82	D004967	estrogen	Chemical	81	82	2	D009203	myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction|myocardial infarction	Disease	6:23:123:138:201:359:409	8:25:125:140:203:361:411	0:1:2:2:4:6:8
12369736	Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine - induced locomotor hyperactivity in rats .|The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the locomotor hyperactivity induced by cocaine in rats .|Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core , and then were locally injected with GR 55562 ( an antagonist of 5 - HT1B receptors ) or CP 93129 ( an agonist of 5 - HT1B receptors ) .|Given alone to any accumbal subregion , GR 55562 ( 0 . 1 - 10 microg / side ) or CP 93129 ( 0 . 1 - 10 microg / side ) did not change basal locomotor activity .|Systemic cocaine ( 10 mg / kg ) significantly increased the locomotor activity of rats .|GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced locomotor hyperactivity .|Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core .|When injected into the accumbens shell ( but not the core ) before cocaine , CP 93129 ( 0 . 1 - 10 microg / side ) enhanced the locomotor response to cocaine ; the maximum effect being observed after 10 microg / side of the agonist .|The later enhancement was attenuated after intra - accumbens shell treatment with GR 55562 ( 1 microg / side ) .|Our findings indicate that cocaine induced hyperlocomotion is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .|In other words , the present results suggest that the accumbal shell 5 - HT1B receptors play a permissive role in the behavioural response to the psychostimulant .	1:CID:2	L2R	NON-CROSS	289-290	291-292	D003042	cocaine|cocaine|cocaine|cocaine|cocaine|cocaine|cocaine	Chemical	16:60:149:184:229:248:289	17:61:150:185:230:249:290	0:1:4:5:7:7:9	D009069	locomotor hyperactivity|locomotor hyperactivity|locomotor hyperactivity|hyperlocomotion	Disease	19:56:194:291	21:58:196:292	0:1:5:9	1:CID:2	R2L	NON-CROSS	231-233	194-196	C065046	CP 93129|CP 93129|CP 93129|CP 93129	Chemical	97:129:231:332	99:131:233:334	2:3:7:9	D009069	locomotor hyperactivity|locomotor hyperactivity|locomotor hyperactivity|hyperlocomotion	Disease	19:56:194:291	21:58:196:292	0:1:5:9	1:NR:2	R2L	NON-CROSS	209-211	194-196	C103477	GR 55562|GR 55562|GR 55562|GR 55562|GR 55562|GR 55562	Chemical	85:116:164:209:276:326	87:118:166:211:278:328	2:3:5:6:8:9	D009069	locomotor hyperactivity|locomotor hyperactivity|locomotor hyperactivity|hyperlocomotion	Disease	19:56:194:291	21:58:196:292	0:1:5:9
12639165	Ticlopidine - induced cholestatic hepatitis .|OBJECTIVE : To report 2 cases of ticlopidine - induced cholestatic hepatitis , investigate its mechanism , and compare the observed main characteristics with those of the published cases .|CASE SUMMARIES : Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty , with complete remission during the follow - up period .|T - cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients , but not in healthy controls .|DISCUSSION : Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine ; several cases have been reported but few in the English literature .|Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .|Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course , but complete remission was observed in all reported cases .|An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine .|The mechanisms of this ticlopidine - induced cholestasis are unclear .|Immune mechanisms may be involved in the drug 's hepatotoxicity , as suggested by the T - cell stimulation study reported here .|CONCLUSIONS : Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated .|Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts .|This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel .	1:CID:2	L2R	NON-CROSS	0-1	3-5	D013988	Ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine	Chemical	0:13:47:71:98:119:182:188:228:265	1:14:48:72:99:120:183:189:229:266	0:1:2:3:4:5:7:8:10:12	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|cholestasis|Cholestatic hepatitis	Disease	3:16:43:88:128:191:220	5:18:45:90:130:192:222	0:1:2:4:5:8:10	1:CID:2	L2R	NON-CROSS	0-1	3-5	D013988	Ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine	Chemical	0:13:47:71:98:119:182:188:228:265	1:14:48:72:99:120:183:189:229:266	0:1:2:3:4:5:7:8:10:12	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|Hepatitis|hepatotoxicity|Cholestatic hepatitis	Disease	3:16:43:88:128:139:204:220	5:18:45:90:130:140:205:222	0:1:2:4:5:6:9:10	1:CID:2	L2R	NON-CROSS	115-116	119-120	D013988	Ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine|ticlopidine	Chemical	0:13:47:71:98:119:182:188:228:265	1:14:48:72:99:120:183:189:229:266	0:1:2:3:4:5:7:8:10:12	D007565	jaundice	Disease	115	116	5	1:NR:2	R2L	CROSS	274-275	220-222	C055162	clopidogrel	Chemical	274	275	12	D002779	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|cholestasis|Cholestatic hepatitis	Disease	3:16:43:88:128:191:220	5:18:45:90:130:192:222	0:1:2:4:5:8:10	1:NR:2	R2L	CROSS	274-275	220-222	C055162	clopidogrel	Chemical	274	275	12	D056486	cholestatic hepatitis|cholestatic hepatitis|cholestatic hepatitis|Cholestatic hepatitis|cholestatic hepatitis|Hepatitis|hepatotoxicity|Cholestatic hepatitis	Disease	3:16:43:88:128:139:204:220	5:18:45:90:130:140:205:222	0:1:2:4:5:6:9:10	1:NR:2	R2L	CROSS	274-275	115-116	C055162	clopidogrel	Chemical	274	275	12	D007565	jaundice	Disease	115	116	5
12653683	Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced nephrotic syndrome .|In experimental nephrotic syndrome , urinary sodium excretion is decreased during the early phase of the disease .|The molecular mechanism ( s ) leading to salt retention has not been completely elucidated .|The rate - limiting constituent of collecting duct sodium transport is the epithelial sodium channel ( ENaC ) .|We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( PAN ) - induced nephrotic syndrome .|The time courses of urinary sodium excretion , plasma aldosterone concentration and proteinuria were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .|The relative amounts of alphaENaC , betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real - time quantitative TaqMan PCR , and the amounts of proteins by Western blot .|The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously .|Sodium retention occurred on days 2 , 3 and 6 after PAN injection .|A significant up - regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3 .|Conversely , down - regulation of alphaENaC , betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations , and was followed by a return of sodium excretion to control values .|The amounts of alphaENaC , betaENaC and gammaENaC proteins were not increased during PAN - induced sodium retention .|In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced nephrotic syndrome in rats , but appears to escape from the regulation by aldosterone after day 3 .	1:CID:2	L2R	NON-CROSS	14-16	18-20	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN|PAN	Chemical	14:85:88:123:190:269:297	16:87:89:124:191:270:298	0:4:4:5:8:11:12	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	Disease	18:23:92:300	20:25:94:302	0:1:4:12	1:CID:2	L2R	NON-CROSS	107-108	123-124	D011692	puromycin aminonucleoside|puromycin aminonucleoside|PAN|PAN|PAN|PAN|PAN	Chemical	14:85:88:123:190:269:297	16:87:89:124:191:270:298	0:4:4:5:8:11:12	D011507	proteinuria|proteinuria	Disease	107:171	108:172	5:7	1:NR:2	L2R	NON-CROSS	23-25	27-28	D012964	sodium|sodium|sodium|sodium|sodium|sodium|Sodium|sodium|sodium|sodium	Chemical	1:27:63:68:100:165:179:210:250:272	2:28:64:69:101:166:180:211:251:273	0:1:3:3:5:7:8:9:10:11	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	Disease	18:23:92:300	20:25:94:302	0:1:4:12	1:NR:2	L2R	NON-CROSS	165-166	171-172	D012964	sodium|sodium|sodium|sodium|sodium|sodium|Sodium|sodium|sodium|sodium	Chemical	1:27:63:68:100:165:179:210:250:272	2:28:64:69:101:166:180:211:251:273	0:1:3:3:5:7:8:9:10:11	D011507	proteinuria|proteinuria	Disease	107:171	108:172	5:7	1:NR:2	R2L	NON-CROSS	104-105	92-94	D000450	aldosterone|aldosterone|aldosterone	Chemical	104:240:313	105:241:314	5:10:12	D009404	nephrotic syndrome|nephrotic syndrome|nephrotic syndrome|nephrotic syndrome	Disease	18:23:92:300	20:25:94:302	0:1:4:12	1:NR:2	L2R	NON-CROSS	104-105	107-108	D000450	aldosterone|aldosterone|aldosterone	Chemical	104:240:313	105:241:314	5:10:12	D011507	proteinuria|proteinuria	Disease	107:171	108:172	5:7
14659530	NO - induced migraine attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .|The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin .|Fifteen female migraineurs ( without aura ) and eight controls participated in the study .|Sublingual nitroglycerin ( 0 . 5 mg ) was administered .|Blood was collected from the antecubital vein four times : 60 min before and after the nitroglycerin application , and 60 and 120 min after the beginning of the migraine attack ( mean 344 and 404 min ; 12 subjects ) .|In those subjects who had no migraine attack ( 11 subjects ) a similar time schedule was used .|Plasma CGRP concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the migraine .|In addition , both change and peak , showed significant positive correlations with migraine headache intensity ( P < 0 . 001 ) .|However , plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack .|Basal CGRP concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a migraine attack .|Platelet serotonin content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack .|In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine .|In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the headache and the concomitant CGRP release in this model .	1:CID:2	L2R	CROSS	0-1	78-83	D009569	NO	Chemical	0	1	0	D020326	migraineurs ( without aura )	Disease	78	83	2	1:CID:2	L2R	CROSS	74-75	78-83	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	74:92:118:271	75:93:119:272	1:3:4:10	D020326	migraineurs ( without aura )	Disease	78	83	2	not_include	L2R	NON-CROSS	0-1	3-4	D009569	NO	Chemical	0	1	0	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	1:NR:2	L2R	CROSS	0-1	65-66	D009569	NO	Chemical	0	1	0	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12	1:NR:2	R2L	NON-CROSS	316-317	314-315	D015740	calcitonin gene - related peptide|CGRP|calcitonin gene - related peptide|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP	Chemical	10:16:40:46:164:217:235:297:314:339	15:17:45:47:165:218:236:298:315:340	0:0:1:1:6:8:9:11:11:12	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	1:NR:2	R2L	NON-CROSS	259-260	255-256	D012701	serotonin|serotonin|5 - hydroxytriptamine|5 - HT|5 - HT|serotonin|serotonin	Chemical	24:51:53:57:242:259:321	25:52:56:60:245:260:322	0:1:1:1:9:10:12	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	not_include	R2L	NON-CROSS	74-75	70-71	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	74:92:118:271	75:93:119:272	1:3:4:10	D008881	migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine|migraine	Disease	3:70:131:150:177:188:203:231:255:276:287:307:316:328	4:71:132:151:178:189:204:232:256:277:288:308:317:329	0:1:4:5:6:6:7:8:9:10:10:11:11:12	1:NR:2	L2R	NON-CROSS	335-336	339-340	D015740	calcitonin gene - related peptide|CGRP|calcitonin gene - related peptide|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP	Chemical	10:16:40:46:164:217:235:297:314:339	15:17:45:47:165:218:236:298:315:340	0:0:1:1:6:8:9:11:11:12	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12	1:NR:2	L2R	CROSS	46-47	78-83	D015740	calcitonin gene - related peptide|CGRP|calcitonin gene - related peptide|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP|CGRP	Chemical	10:16:40:46:164:217:235:297:314:339	15:17:45:47:165:218:236:298:315:340	0:0:1:1:6:8:9:11:11:12	D020326	migraineurs ( without aura )	Disease	78	83	2	1:NR:2	L2R	NON-CROSS	57-60	65-66	D012701	serotonin|serotonin|5 - hydroxytriptamine|5 - HT|5 - HT|serotonin|serotonin	Chemical	24:51:53:57:242:259:321	25:52:56:60:245:260:322	0:1:1:1:9:10:12	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12	1:NR:2	L2R	CROSS	57-60	78-83	D012701	serotonin|serotonin|5 - hydroxytriptamine|5 - HT|5 - HT|serotonin|serotonin	Chemical	24:51:53:57:242:259:321	25:52:56:60:245:260:322	0:1:1:1:9:10:12	D020326	migraineurs ( without aura )	Disease	78	83	2	1:NR:2	R2L	NON-CROSS	74-75	65-66	D005996	nitroglycerin|nitroglycerin|nitroglycerin|nitroglycerin	Chemical	74:92:118:271	75:93:119:272	1:3:4:10	D006261	headache|headache|headache|headache|headache	Disease	65:204:224:308:335	66:205:225:309:336	1:7:8:11:12
15804801	Coronary aneurysm after implantation of a paclitaxel - eluting stent .|Formation of coronary aneurysm is a rare complication of stenting with bare metal stents , but based on experimental studies drug - eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition , aneurysm formation and with the potential of stent thrombosis or vessel rupture .|We present a 43 - year - old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel - eluting stent .|The patient was asymptomatic and the aneurysm was detected in a routine control .|Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15 - mm long segment with maximal aneurysm diameter of 6 . 0 mm .|The patient was successfully treated with a graft stent .	1:CID:2	R2L	NON-CROSS	6-7	0-2	D017239	paclitaxel|paclitaxel	Chemical	6:85	7:86	0:2	D003323	Coronary aneurysm|coronary aneurysm|coronary aneurysm	Disease	0:13:73	2:15:75	0:1:2	not_include	L2R	CROSS	85-86	96-97	D017239	paclitaxel|paclitaxel	Chemical	6:85	7:86	0:2	D000783	aneurysm|aneurysm|aneurysm	Disease	48:96:126	49:97:127	1:3:4	1:NR:2	L2R	CROSS	56-57	85-86	D017239	paclitaxel|paclitaxel	Chemical	6:85	7:86	0:2	D013927	thrombosis	Disease	56	57	1
16160878	Behavioral effects of urotensin - II centrally administered in mice .|Urotensin - II ( U - II ) receptors are widely distributed in the central nervous system .|Intracerebroventricular ( i . c . v . ) injection of U - II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion .|However , the behavioral effects of centrally administered U - II have received little attention .|In the present study , we tested the effects of i . c . v .|injections of U - II on behavioral , metabolic , and endocrine responses in mice .|Administration of graded doses of U - II ( 1 - 10 , 000 ng / mouse ) provoked : ( 1 ) a dose - dependent reduction in the number of head dips in the hole - board test ; ( 2 ) a dose - dependent reduction in the number of entries in the white chamber in the black - and - white compartment test , and in the number of entries in the central platform and open arms in the plus - maze test ; and ( 3 ) a dose - dependent increase in the duration of immobility in the forced - swimming test and tail suspension test .|Intracerebroventricular injection of U - II also caused an increase in : food intake at doses of 100 and 1 , 000 ng / mouse , water intake at doses of 100 - 10 , 000 ng / mouse , and horizontal locomotion activity at a dose of 10 , 000 ng / mouse .|Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced penile erection and climbing behavior , and stress - induced plasma corticosterone level .|Taken together , the present study demonstrates that the central injection of U - II at doses of 1 - 10 , 000 ng / mouse induces anxiogenic - and depressant - like effects in mouse .|These data suggest that U - II may be involved in some aspects of psychiatric disorders .	1:CID:2	L2R	NON-CROSS	291-292	294-296	D001058	apomorphine	Chemical	291	292	8	D010409	penile erection	Disease	294	296	8	1:NR:2	L2R	NON-CROSS	40-43	44-45	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D006973	hypertension	Disease	44	45	2	1:NR:2	L2R	NON-CROSS	40-43	46-47	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D001919	bradycardia	Disease	46	47	2	1:NR:2	L2R	NON-CROSS	279-282	294-296	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D010409	penile erection	Disease	294	296	8	1:NR:2	L2R	NON-CROSS	349-352	359-361	D014579	urotensin - II|Urotensin - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II|U - II	Chemical	3:11:15:40:62:88:107:218:279:320:349	6:14:18:43:65:91:110:221:282:323:352	0:1:1:2:3:5:6:7:8:9:10	D001523	psychiatric disorders	Disease	359	361	10	1:NR:2	R2L	CROSS	291-292	44-45	D001058	apomorphine	Chemical	291	292	8	D006973	hypertension	Disease	44	45	2	1:NR:2	R2L	CROSS	305-306	44-45	D003345	corticosterone	Chemical	305	306	8	D006973	hypertension	Disease	44	45	2	1:NR:2	R2L	CROSS	291-292	46-47	D001058	apomorphine	Chemical	291	292	8	D001919	bradycardia	Disease	46	47	2	1:NR:2	R2L	CROSS	305-306	46-47	D003345	corticosterone	Chemical	305	306	8	D001919	bradycardia	Disease	46	47	2	1:NR:2	L2R	CROSS	291-292	359-361	D001058	apomorphine	Chemical	291	292	8	D001523	psychiatric disorders	Disease	359	361	10	1:NR:2	R2L	NON-CROSS	305-306	294-296	D003345	corticosterone	Chemical	305	306	8	D010409	penile erection	Disease	294	296	8	1:NR:2	L2R	CROSS	305-306	359-361	D003345	corticosterone	Chemical	305	306	8	D001523	psychiatric disorders	Disease	359	361	10
16274958	Recurrent dysphonia and acitretin .|We report the case of a woman complaining of dysphonia while she was treated by acitretin .|Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced .|To our knowledge , this is the first case of acitretin - induced dysphonia .|This effect may be related to the pharmacological effect of this drug on mucous membranes .	1:CID:2	R2L	NON-CROSS	3-4	1-2	D017255	acitretin|acitretin|acitretin|acitretin	Chemical	3:20:32:46	4:21:33:47	0:1:2:3	D055154	dysphonia|dysphonia|dysphonia	Disease	1:14:49	2:15:50	0:1:3
16330766	Pharmacological modulation of pain - related brain activity during normal and central sensitization states in humans .|Abnormal processing of somatosensory inputs in the central nervous system ( central sensitization ) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury ( secondary hyperalgesia ) .|Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain .|Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization .|The aim of this study was to assess the effects of gabapentin , a drug effective in neuropathic pain patients , on brain processing of nociceptive information in normal and central sensitization states .|Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced secondary hyperalgesia .|The dose of gabapentin was 1 , 800 mg per os , in a single administration .|We found that ( i ) gabapentin reduced the activations in the bilateral operculoinsular cortex , independently of the presence of central sensitization ; ( ii ) gabapentin reduced the activation in the brainstem , only during central sensitization ; ( iii ) gabapentin suppressed stimulus - induced deactivations , only during central sensitization ; this effect was more robust than the effect on brain activation .|The observed drug - induced effects were not due to changes in the baseline fMRI signal .|These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation , thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present .	1:CID:2	R2L	NON-CROSS	158-160	155-156	D002211	capsaicin	Chemical	155	156	5	D006930	secondary hyperalgesia|Secondary hyperalgesia|neurogenic hyperalgesia|hyperalgesia|secondary hyperalgesia	Disease	47:51:57:77:158	49:53:59:78:160	1:2:2:3:5	1:NR:2	R2L	CROSS	100-101	38-39	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D010146	pain|pain	Disease	3:38	4:39	0:1	1:NR:2	R2L	CROSS	155-156	38-39	D002211	capsaicin	Chemical	155	156	5	D010146	pain|pain	Disease	3:38	4:39	0:1	1:NR:2	R2L	CROSS	100-101	44-46	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D017695	tissue injury	Disease	44	46	1	1:NR:2	R2L	CROSS	155-156	44-46	D002211	capsaicin	Chemical	155	156	5	D017695	tissue injury	Disease	44	46	1	1:NR:2	R2L	NON-CROSS	164-165	158-160	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D006930	secondary hyperalgesia|Secondary hyperalgesia|neurogenic hyperalgesia|hyperalgesia|secondary hyperalgesia	Disease	47:51:57:77:158	49:53:59:78:160	1:2:2:3:5	1:NR:2	R2L	NON-CROSS	106-108	100-101	C040029	gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin|gabapentin	Chemical	100:138:164:184:205:221:266:291	101:139:165:185:206:222:267:292	4:5:6:7:7:7:9:9	D009437	neuropathic pain|neuropathic pain	Disease	62:106	64:108	2:4	1:NR:2	R2L	CROSS	155-156	106-108	D002211	capsaicin	Chemical	155	156	5	D009437	neuropathic pain|neuropathic pain	Disease	62:106	64:108	2:4
16574712	MDMA polydrug users show process - specific central executive impairments coupled with impaired social and emotional judgement processes .|In recent years working memory deficits have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .|The current study aimed to assess the impact of MDMA use on three separate central executive processes ( set shifting , inhibition and memory updating ) and also on " prefrontal " mediated social and emotional judgement processes .|Fifteen polydrug ecstasy users and 15 polydrug non - ecstasy user controls completed a general drug use questionnaire , the Brixton Spatial Anticipation task ( set shifting ) , Backward Digit Span procedure ( memory updating ) , Inhibition of Return ( inhibition ) , an emotional intelligence scale , the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire ( DEX ) .|Compared with MDMA - free polydrug controls , MDMA polydrug users showed impairments in set shifting and memory updating , and also in social and emotional judgement processes .|The latter two deficits remained significant after controlling for other drug use .|These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use .	1:CID:2	L2R	NON-CROSS	0-1	12-18	D018817	MDMA|MDMA|3 , 4 - methylenedioxymethamphetamine|ecstasy|MDMA|ecstasy|ecstasy|MDMA|MDMA|ecstasy	Chemical	0:31:33:39:51:83:90:146:152:207	1:32:38:40:52:84:91:147:153:208	0:1:1:1:2:3:3:4:4:6	D003072	impaired social and emotional judgement processes	Disease	12	18	0	1:NR:2	L2R	NON-CROSS	23-25	31-32	D018817	MDMA|MDMA|3 , 4 - methylenedioxymethamphetamine|ecstasy|MDMA|ecstasy|ecstasy|MDMA|MDMA|ecstasy	Chemical	0:31:33:39:51:83:90:146:152:207	1:32:38:40:52:84:91:147:153:208	0:1:1:1:2:3:3:4:4:6	D008569	memory deficits	Disease	23	25	1
17111419	Severe citrate toxicity complicating volunteer apheresis platelet donation .|We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection .|The donor was a 40 - year - old female , first - time apheresis platelet donor .|Past medical history was remarkable for hypertension , hyperlipidemia , and depression .|Reported medications included bumetanide , pravastatin , and paroxetine .|Thirty minutes from the start of the procedure , the donor noted tingling around the mouth , hands , and feet .|She then very rapidly developed acute onset of severe facial and extremity tetany .|Empirical treatment with intravenous calcium gluconate was initiated , and muscle contractions slowly subsided over approximately 10 to 15 minutes .|The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia .|Upon additional retrospective analysis , it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia .|We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity .|Laboratory measurement of pre - procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance .|The case also illustrates the importance of maintaining preparedness for managing rare but serious reactions in volunteer apheresis blood donors .	1:CID:2	L2R	NON-CROSS	134-136	141-142	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	L2R	NON-CROSS	1-2	2-3	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	L2R	CROSS	15-16	48-49	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D006973	hypertension	Disease	48	49	3	1:NR:2	L2R	CROSS	15-16	50-51	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	L2R	CROSS	15-16	53-54	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D003866	depression	Disease	53	54	3	1:NR:2	L2R	CROSS	99-100	134-136	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	111-113	134-136	C102006	citrate|citrate|sodium citrate|citrate	Chemical	1:15:134:185	2:16:136:186	0:1:8:10	C536214	muscle contractions	Disease	111	113	7	1:NR:2	R2L	CROSS	186-187	152-153	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	60-61	16-17	D017035	pravastatin	Chemical	60	61	4	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	63-64	16-17	D017374	paroxetine	Chemical	63	64	4	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	186-187	105-107	D002125	calcium gluconate	Chemical	105	107	7	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	195-196	186-187	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	186-187	155-157	D049994	loop diuretic	Chemical	155	157	9	D064420	toxicity|toxicity|toxicity	Disease	2:16:186	3:17:187	0:1:10	1:NR:2	R2L	CROSS	58-59	48-49	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	60-61	48-49	D017035	pravastatin	Chemical	60	61	4	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	63-64	48-49	D017374	paroxetine	Chemical	63	64	4	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	105-107	48-49	D002125	calcium gluconate	Chemical	105	107	7	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	131-132	48-49	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	155-157	48-49	D049994	loop diuretic	Chemical	155	157	9	D006973	hypertension	Disease	48	49	3	1:NR:2	R2L	CROSS	58-59	50-51	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	60-61	50-51	D017035	pravastatin	Chemical	60	61	4	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	63-64	50-51	D017374	paroxetine	Chemical	63	64	4	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	105-107	50-51	D002125	calcium gluconate	Chemical	105	107	7	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	131-132	50-51	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	155-157	50-51	D049994	loop diuretic	Chemical	155	157	9	D006949	hyperlipidemia	Disease	50	51	3	1:NR:2	R2L	CROSS	58-59	53-54	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	60-61	53-54	D017035	pravastatin	Chemical	60	61	4	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	63-64	53-54	D017374	paroxetine	Chemical	63	64	4	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	105-107	53-54	D002125	calcium gluconate	Chemical	105	107	7	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	131-132	53-54	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D003866	depression	Disease	53	54	3	1:NR:2	R2L	CROSS	155-157	53-54	D049994	loop diuretic	Chemical	155	157	9	D003866	depression	Disease	53	54	3	1:NR:2	L2R	CROSS	58-59	99-100	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	111-113	152-153	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	NON-CROSS	152-153	161-162	D002034	bumetanide|bumetanide	Chemical	58:152	59:153	4:9	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	L2R	CROSS	60-61	99-100	D017035	pravastatin	Chemical	60	61	4	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	60-61	111-113	D017035	pravastatin	Chemical	60	61	4	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	CROSS	60-61	141-142	D017035	pravastatin	Chemical	60	61	4	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	L2R	CROSS	63-64	99-100	D017374	paroxetine	Chemical	63	64	4	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	CROSS	63-64	111-113	D017374	paroxetine	Chemical	63	64	4	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	CROSS	63-64	141-142	D017374	paroxetine	Chemical	63	64	4	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	R2L	CROSS	105-107	99-100	D002125	calcium gluconate	Chemical	105	107	7	D013746	tetany	Disease	99	100	6	1:NR:2	R2L	CROSS	131-132	99-100	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D013746	tetany	Disease	99	100	6	1:NR:2	R2L	CROSS	155-157	99-100	D049994	loop diuretic	Chemical	155	157	9	D013746	tetany	Disease	99	100	6	1:NR:2	L2R	NON-CROSS	105-107	111-113	D002125	calcium gluconate	Chemical	105	107	7	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	CROSS	105-107	141-142	D002125	calcium gluconate	Chemical	105	107	7	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	R2L	CROSS	131-132	111-113	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	C536214	muscle contractions	Disease	111	113	7	1:NR:2	R2L	CROSS	155-157	111-113	D049994	loop diuretic	Chemical	155	157	9	C536214	muscle contractions	Disease	111	113	7	1:NR:2	L2R	NON-CROSS	131-132	141-142	D002118	calcium|calcium	Chemical	131:195	132:196	8:11	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10	1:NR:2	R2L	NON-CROSS	161-162	155-157	D049994	loop diuretic	Chemical	155	157	9	D006996	hypocalcemia|hypocalcemia|hypocalcemia	Disease	141:161:175	142:162:176	8:9:10
17175308	Proteinuria after conversion to sirolimus in renal transplant recipients .|Sirolimus ( SRL ) is a new , potent immunosuppressive agent .|More recently , proteinuria has been reported as a consequence of sirolimus therapy , although the mechanism has remained unclear .|We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased proteinuria after SRL conversion .|The patient cohort ( 14 men , 11 women ) was treated with SRL as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi 's sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .|SRL was started at a mean of 78 + / - 42 ( 15 to 163 ) months after transplantation .|Mean follow - up on SRL therapy was 20 + / - 12 ( 6 to 43 ) months .|Proteinuria increased from 0 . 445 ( 0 to 1 . 5 ) g / d before conversion to 3 . 2 g / dL ( 0 . 2 to 12 ) after conversion ( P = 0 . 001 ) .|Before conversion 8 ( 32 % ) patients had no proteinuria , whereas afterwards all patients had proteinuria .|In 28 % of patients proteinuria remained unchanged , whereas it increased in 68 % of patients .|In 40 % it increased by more than 100 % .|Twenty - eight percent of patients showed increased proteinuria to the nephrotic range .|Biopsies performed in five patients revealed new pathological changes : One membranoproliferative glomerulopathy and interstitial nephritis .|These patients showed persistently good graft function .|Serum creatinine values did not change significantly : 1 . 98 + / - 0 . 8 mg / dL before SRL therapy and 2 . 53 + / - 1 . 9 mg / dL at last follow - up ( P = . 14 ) .|Five grafts were lost and the patients returned to dialysis .|Five patients displayed CAN and Kaposi 's sarcoma .|Mean urinary protein of patients who returned to dialysis was 1 . 26 ( 0 . 5 to 3 . 5 ) g / d before and 4 . 7 ( 3 to 12 ) g / d after conversion ( P = . 01 ) .|Mean serum creatinine level before conversion was 2 . 21 mg / dL and thereafter , 4 . 93 mg / dL ( P = . 02 ) .|Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation .|Therefore , conversion should be considered for patients who have not developed advanced CAN and proteinuria .|The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy .	1:CID:2	R2L	NON-CROSS	61-62	59-60	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D011507	Proteinuria|proteinuria|proteinuria|Proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria	Disease	0:25:59:170:222:229:236:268:444:474	1:26:60:171:223:230:237:269:445:475	0:2:3:7:8:8:9:11:19:20	1:NR:2	R2L	CROSS	444-445	416-417	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D011507	Proteinuria|proteinuria|proteinuria|Proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria|proteinuria	Disease	0:25:59:170:222:229:236:268:444:474	1:26:60:171:223:230:237:269:445:475	0:2:3:7:8:8:9:11:19:20	1:NR:2	L2R	NON-CROSS	77-78	84-87	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D051436	chronic allograft nephropathy	Disease	84	87	4	1:NR:2	L2R	NON-CROSS	122-123	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D007674	CAN|nephropathy|CAN|CAN	Disease	88:122:361:472	89:123:362:473	4:4:16:20	1:NR:2	L2R	NON-CROSS	77-78	95-96	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D009369	neoplasia	Disease	95	96	4	1:NR:2	L2R	NON-CROSS	77-78	102-105	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D012514	Kaposi 's sarcoma|Kaposi 's sarcoma	Disease	102:363	105:366	4:16	1:NR:2	L2R	NON-CROSS	107-109	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D012878	skin cancers	Disease	107	109	4	1:NR:2	L2R	NON-CROSS	111-113	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D007414	intestinal tumors	Disease	111	113	4	1:NR:2	L2R	NON-CROSS	115-118	129-130	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D002292	renal cell carsinom	Disease	115	118	4	1:NR:2	L2R	CROSS	271-272	320-321	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D009404	nephrotic	Disease	271	272	11	1:NR:2	L2R	CROSS	285-287	320-321	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D015433	membranoproliferative glomerulopathy	Disease	285	287	12	1:NR:2	L2R	CROSS	288-290	320-321	D020123	sirolimus|Sirolimus|SRL|sirolimus|SRL|SRL|SRL|SRL|SRL|SRL|SRL	Chemical	4:10:12:33:61:77:129:155:320:451:484	5:11:13:34:62:78:130:156:321:452:485	0:1:1:2:3:4:5:6:14:19:21	D009395	interstitial nephritis	Disease	288	290	12	1:NR:2	R2L	CROSS	300-301	84-87	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D051436	chronic allograft nephropathy	Disease	84	87	4	1:NR:2	R2L	CROSS	416-417	361-362	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D007674	CAN|nephropathy|CAN|CAN	Disease	88:122:361:472	89:123:362:473	4:4:16:20	1:NR:2	R2L	CROSS	300-301	95-96	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D009369	neoplasia	Disease	95	96	4	1:NR:2	R2L	CROSS	416-417	363-366	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D012514	Kaposi 's sarcoma|Kaposi 's sarcoma	Disease	102:363	105:366	4:16	1:NR:2	R2L	CROSS	300-301	107-109	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D012878	skin cancers	Disease	107	109	4	1:NR:2	R2L	CROSS	300-301	111-113	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D007414	intestinal tumors	Disease	111	113	4	1:NR:2	R2L	CROSS	300-301	115-118	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D002292	renal cell carsinom	Disease	115	118	4	1:NR:2	R2L	CROSS	300-301	271-272	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D009404	nephrotic	Disease	271	272	11	1:NR:2	R2L	CROSS	300-301	285-287	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D015433	membranoproliferative glomerulopathy	Disease	285	287	12	1:NR:2	R2L	CROSS	300-301	288-290	D003404	creatinine|creatinine	Chemical	300:416	301:417	14:18	D009395	interstitial nephritis	Disease	288	290	12
17244258	In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide - induced cystitis in the rat .|In cyclophosphamide - induced cystitis in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .|Whether or not the neuronal transmission may be affected by cystitis was presently investigated .|Responses of urinary strip preparations from control and cyclophosphamide - pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic , adrenergic and purinergic receptor antagonists .|Generally , atropine reduced contractions , but in contrast to controls , it also reduced responses to low electrical field stimulation intensity ( 1 - 5 Hz ) in inflamed preparations .|In both types , purinoceptor desensitization with alpha , beta - methylene adenosine - 5 ' - triphosphate ( alpha , beta - meATP ) caused further reductions at low frequencies ( < 10 Hz ) .|The muscarinic receptor antagonists atropine , 4 - diphenylacetoxy - N - methylpiperidine ( 4 - DAMP ) ( ' M ( 1 ) / M ( 3 ) / M ( 5 ) - selective ' ) , methoctramine ( ' M ( 2 ) - selective ' ) and pirenzepine ( ' M ( 1 ) - selective ' ) antagonized the tonic component of the electrical field stimulation - evoked contractile response more potently than the phasic component .|4 - DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine .|In inflamed preparations , the muscarinic receptor antagonism on the phasic component of the electrical field stimulation - evoked contraction was decreased and the pirenzepine and 4 - DAMP antagonism on the tonic component was much less efficient than in controls .|In contrast to controls , methoctramine increased - - instead of decreased - - the tonic responses at high frequencies .|While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response , isoprenaline - induced relaxations were smaller in inflamed strips .|Thus , in cystitis substantial changes of the efferent functional responses occur .|While postjunctional beta - adrenoceptor - mediated relaxations are reduced , effects by prejunctional inhibitory muscarinic receptors may be increased .	1:CID:2	L2R	NON-CROSS	9-10	12-13	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide	Chemical	9:18:63	10:19:64	0:1:3	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	92-93	50-51	D001285	atropine|atropine	Chemical	92:163	93:164	4:6	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	129-140	50-51	C002630	alpha , beta - methylene adenosine - 5 ' - triphosphate|alpha , beta - meATP	Chemical	129:141	140:146	5:5	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	283-286	C042375	4 - diphenylacetoxy - N - methylpiperidine|4 - DAMP|4 - DAMP|4 - DAMP	Chemical	165:173:241:283	172:176:244:286	6:6:7:8	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	304-305	C054938	methoctramine|methoctramine|methoctramine	Chemical	198:253:304	199:254:305	6:7:9	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	281-282	D010890	pirenzepine|pirenzepine|pirenzepine	Chemical	210:255:281	211:256:282	6:7:8	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	323-324	D002217	carbachol	Chemical	323	324	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	325-326	D000255	ATP	Chemical	325	326	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	340-341	D011188	potassium	Chemical	340	341	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11	1:NR:2	R2L	CROSS	356-357	343-344	D007545	isoprenaline	Chemical	343	344	10	D003556	cystitis|cystitis|cystitis|cystitis	Disease	12:21:50:356	13:22:51:357	0:1:2:11
18020536	Associations between use of benzodiazepines or related drugs and health , physical abilities and cognitive function : a non - randomised clinical study in the elderly .|OBJECTIVE : To describe associations between the use of benzodiazepines or related drugs ( BZDs / RDs ) and health , functional abilities and cognitive function in the elderly .|METHODS : A non - randomised clinical study of patients aged > or = 65 years admitted to acute hospital wards during 1 month .|164 patients ( mean age + / - standard deviation [ SD ] 81 . 6 + / - 6 . 8 years ) were admitted .|Of these , nearly half ( n = 78 ) had used BZDs / RDs before admission , and the remainder ( n = 86 ) were non - users .|Cognitive ability was assessed by the Mini - Mental State Examination ( MMSE ) .|Patients scoring > or = 20 MMSE sum points were interviewed ( n = 79 ) and questioned regarding symptoms and functional abilities during the week prior to admission .|Data on use of BZDs / RDs before admission , current medications and discharge diagnoses were collected from medical records .|Health , physical abilities and cognitive function were compared between BZD / RD users and non - users , and adjustments were made for confounding variables .|The residual serum concentrations of oxazepam , temazepam and zopiclone were analysed .|RESULTS : The mean + / - SD duration of BZD / RD use was 7 + / - 7 years ( range 1 - 31 ) .|Two or three BZDs / RDs were concomitantly taken by 26 % of users ( n = 20 ) .|Long - term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS , which tended to be related to diagnosed dementia .|After adjustment for these variables as confounders , use of BZDs / RDs was not associated with cognitive function as measured by the MMSE .|However , use of BZDs / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .|Use of BZDs / RDs tended to be associated with a reduced ability to walk and shorter night - time sleep during the week prior to admission .|A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables .|CONCLUSIONS : Long - term use and concomitant use of more than one BZD / RD were common in elderly patients hospitalised because of acute illnesses .|Long - term use was associated with daytime and night - time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs .	1:CID:2	L2R	NON-CROSS	358-359	364-365	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D004244	dizziness	Disease	364	365	14	1:CID:2	L2R	NON-CROSS	358-359	366-369	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D007319	inability to sleep	Disease	366	369	14	1:CID:2	L2R	NON-CROSS	358-359	374-375	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D005221	tiredness	Disease	374	375	14	1:CID:2	L2R	NON-CROSS	387-389	400-401	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D003866	depressive symptoms	Disease	387	389	14	1:NR:2	L2R	CROSS	327-328	339-340	D001569	benzodiazepines|benzodiazepines|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs|BZDs	Chemical	4:36:41:121:189:277:339:358:400	5:37:42:122:190:278:340:359:401	0:1:1:4:7:11:13:14:15	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	238-239	327-328	D010076	oxazepam	Chemical	238	239	9	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	238-239	364-365	D010076	oxazepam	Chemical	238	239	9	D004244	dizziness	Disease	364	365	14	1:NR:2	L2R	CROSS	238-239	366-369	D010076	oxazepam	Chemical	238	239	9	D007319	inability to sleep	Disease	366	369	14	1:NR:2	L2R	CROSS	238-239	374-375	D010076	oxazepam	Chemical	238	239	9	D005221	tiredness	Disease	374	375	14	1:NR:2	L2R	CROSS	238-239	387-389	D010076	oxazepam	Chemical	238	239	9	D003866	depressive symptoms	Disease	387	389	14	1:NR:2	L2R	CROSS	240-241	327-328	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	364-365	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D004244	dizziness	Disease	364	365	14	1:NR:2	L2R	CROSS	366-369	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D007319	inability to sleep	Disease	366	369	14	1:NR:2	L2R	CROSS	374-375	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D005221	tiredness	Disease	374	375	14	1:NR:2	L2R	CROSS	387-389	432-433	D013693	temazepam|temazepam	Chemical	240:432	241:433	9:16	D003866	depressive symptoms	Disease	387	389	14	1:NR:2	L2R	CROSS	242-243	327-328	C515050	zopiclone	Chemical	242	243	9	D003704	dementia	Disease	327	328	12	1:NR:2	L2R	CROSS	242-243	364-365	C515050	zopiclone	Chemical	242	243	9	D004244	dizziness	Disease	364	365	14	1:NR:2	L2R	CROSS	242-243	366-369	C515050	zopiclone	Chemical	242	243	9	D007319	inability to sleep	Disease	366	369	14	1:NR:2	L2R	CROSS	242-243	374-375	C515050	zopiclone	Chemical	242	243	9	D005221	tiredness	Disease	374	375	14	1:NR:2	L2R	CROSS	242-243	387-389	C515050	zopiclone	Chemical	242	243	9	D003866	depressive symptoms	Disease	387	389	14
18023325	Acute vocal fold palsy after acute disulfiram intoxication .|Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy .|A 49 - year - old woman was transferred to our department because of quadriparesis , lancinating pain , sensory loss , and paresthesia of the distal limbs .|One month previously , she had taken a single high dose of disulfiram ( 130 tablets of ALCOHOL STOP TAB , Shin - Poong Pharm .|Co . , Ansan , Korea ) in a suicide attempt .|She was not an alcoholic .|For the first few days after ingestion , she was in a confused state and had mild to moderate ataxia and giddiness .|She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state .|A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy .|Laryngeal electromyography ( thyroarytenoid muscle ) showed ample denervation potentials .|Laryngoscopy revealed asymmetric vocal fold movements during phonation .|Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer .|This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose disulfiram intoxication .	1:CID:2	R2L	NON-CROSS	6-7	1-4	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D014826	vocal fold palsy|vocal fold palsy	Disease	1:29	4:32	0:1	1:CID:2	L2R	NON-CROSS	6-7	10-12	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010523	peripheral neuropathy	Disease	10	12	1	1:CID:2	L2R	CROSS	47-48	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D011782	quadriparesis	Disease	47	48	2	1:CID:2	L2R	CROSS	50-51	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010146	pain	Disease	50	51	2	1:CID:2	L2R	CROSS	56-57	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010292	paresthesia	Disease	56	57	2	1:CID:2	L2R	CROSS	74-75	125-126	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D001259	ataxia	Disease	125	126	6	1:NR:2	R2L	CROSS	79-80	29-32	D000431	ALCOHOL	Chemical	79	80	3	D014826	vocal fold palsy|vocal fold palsy	Disease	1:29	4:32	0:1	1:NR:2	L2R	NON-CROSS	15-16	16-17	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D062787	overdose	Disease	16	17	1	1:NR:2	L2R	CROSS	52-54	74-75	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	C580162	sensory loss	Disease	52	54	2	1:NR:2	L2R	CROSS	74-75	127-128	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D004244	giddiness	Disease	127	128	6	1:NR:2	L2R	CROSS	74-75	131-132	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D006685	hoarseness	Disease	131	132	7	1:NR:2	L2R	NON-CROSS	212-213	218-219	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D011115	polyneuropathy|polyneuropathy	Disease	157:212	158:213	8:12	not_include	L2R	NON-CROSS	200-201	218-219	D004221	disulfiram|disulfiram|disulfiram|disulfiram	Chemical	6:15:74:218	7:16:75:219	0:1:3:12	D010243	palsy	Disease	200	201	12	1:NR:2	R2L	CROSS	79-80	10-12	D000431	ALCOHOL	Chemical	79	80	3	D010523	peripheral neuropathy	Disease	10	12	1	1:NR:2	R2L	CROSS	79-80	16-17	D000431	ALCOHOL	Chemical	79	80	3	D062787	overdose	Disease	16	17	1	1:NR:2	R2L	CROSS	79-80	47-48	D000431	ALCOHOL	Chemical	79	80	3	D011782	quadriparesis	Disease	47	48	2	1:NR:2	R2L	CROSS	79-80	50-51	D000431	ALCOHOL	Chemical	79	80	3	D010146	pain	Disease	50	51	2	1:NR:2	R2L	CROSS	79-80	52-54	D000431	ALCOHOL	Chemical	79	80	3	C580162	sensory loss	Disease	52	54	2	1:NR:2	R2L	CROSS	79-80	56-57	D000431	ALCOHOL	Chemical	79	80	3	D010292	paresthesia	Disease	56	57	2	1:NR:2	L2R	CROSS	79-80	125-126	D000431	ALCOHOL	Chemical	79	80	3	D001259	ataxia	Disease	125	126	6	1:NR:2	L2R	CROSS	79-80	127-128	D000431	ALCOHOL	Chemical	79	80	3	D004244	giddiness	Disease	127	128	6	1:NR:2	L2R	CROSS	79-80	131-132	D000431	ALCOHOL	Chemical	79	80	3	D006685	hoarseness	Disease	131	132	7	1:NR:2	L2R	CROSS	79-80	157-158	D000431	ALCOHOL	Chemical	79	80	3	D011115	polyneuropathy|polyneuropathy	Disease	157:212	158:213	8:12	1:NR:2	L2R	CROSS	79-80	200-201	D000431	ALCOHOL	Chemical	79	80	3	D010243	palsy	Disease	200	201	12
18208574	Higher optical density of an antigen assay predicts thrombosis in patients with heparin - induced thrombocytopenia .|OBJECTIVES : To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .|PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or thrombocytopenia ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .|RESULTS : Forty of 94 HIT patients had thrombosis at diagnosis ; 54 / 94 had isolated - HIT without thrombosis .|Eight of the isolated - HIT patients developed thrombosis within the next 30 d ; thus , a total of 48 patients had thrombosis at day 30 .|At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated - HIT .|However , OD was significantly higher in all patients with thrombosis ( n = 48 , 1 . 34 + / - 0 . 89 ) , including isolated - HIT patients who later developed thrombosis within 30 d ( n = 8 , 1 . 84 + / - 0 . 64 ) as compared to isolated - HIT patients who did not develop thrombosis ( 0 . 96 + / - 0 . 75 ; P = 0 . 011 and P = 0 . 008 ) .|The Receiver Operative Characteristic Curve showed that OD > 1 . 27 in the isolated - HIT group had a significantly higher chance of developing thrombosis by day 30 .|None of these groups showed significant difference in percent inhibition .|Multivariate analysis showed a 2 . 8 - fold increased risk of thrombosis in females .|Similarly , thrombotic risk increased with age and OD values .|CONCLUSION : Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated - HIT ; percent inhibition , however , was not predictive .	1:CID:2	R2L	NON-CROSS	12-13	8-9	D006493	heparin|heparin|heparin|heparin|heparin	Chemical	12:31:52:85:114	13:32:53:86:115	0:1:1:2:2	D013927	thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombosis|thrombotic|thrombosis	Disease	8:41:130:142:152:167:185:203:228:258:308:336:342:362	9:42:131:143:153:168:186:204:229:259:309:337:343:363	0:1:3:3:4:4:5:6:6:6:7:9:10:11	1:CID:2	L2R	NON-CROSS	12-13	15-16	D006493	heparin|heparin|heparin|heparin|heparin	Chemical	12:31:52:85:114	13:32:53:86:115	0:1:1:2:2	D013921	thrombocytopenia|thrombocytopenia|HIT|thrombocytopenia|HIT|HIT|HIT|HIT|HIT|HIT|HIT|HIT|HIT	Disease	15:34:36:70:127:140:149:182:191:223:252:299:368	16:35:37:71:128:141:150:183:192:224:253:300:369	0:1:1:2:3:3:4:5:5:6:6:7:11
